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Dedicated to my family 
 
“It is always wise to look ahead, but difficult to look further than you can see” 
Winston Churchill 
 
 
 
 ABSTRACT 
Synaptic loss is the major correlate for cognitive decline in Alzheimer disease (AD). Processes 
taking place in the synapses are highly energy demanding and needs strict regulation, which 
makes the mitochondria and ER crucial at these sites so as to supply energy and spatially regulate 
intracellular calcium signaling. The ER and mitochondria interact with each other at a highly 
specialized region of ER called the mitochondria-associated ER membrane (MAM). At the MAM 
several processes are regulated, including calcium handling, metabolism of glucose, phospholipids 
and cholesterol as well as apoptosis, all of which are deranged in AD. The aim of this thesis was 
to obtain deeper understanding of processes that could be behind mitochondrial dysfunction and 
caspase activation, and thereby cause synapse loss. Caspases are activated both during normal 
plasticity and in apoptosis, and their activation is associated with elevated Aβ production. In 
Paper I, we studied this relationship and showed that during caspase activation intracellular 
Aβ42/Aβ40 ratio increases due to caspase cleavage of presenilin 1 (PS1) residing in active γ-
secretase complexes. Intracellular Aβ is cytotoxic and interferes with various processes for 
example intra-mitochondrial accumulation cause damage to mitochondrial functions. Aβ is 
imported into the mitochondria via the TOM40 pore. A specific polymorphic poly-T variant 
(rs10524523), in the TOMM40 gene had been postulated to cause earlier disease onset of late-
onset AD (LOAD) in APOE ε3/ε4 carriers. Knowing the importance of TOM40 protein we set 
out, in Paper II, to investigate the functional implication of this polymorphism. However, we 
could not identify any deficits in mitochondrial function or morphology. Nevertheless, the 
mitochondria are evidently affected by AD, as indication include altered calcium homeostasis and 
metabolism. These alterations can be linked to the MAM region, which is a region scarcely 
investigated in the brain. Therefore, in Paper III, studying MAM, we showed that it exists in 
synapses and is essential for both neuronal and astrocytic survival. Furthermore, we showed that 
MAM is altered in human AD brain as well as in APPSwe/Lon mice, and is so before the appearance 
of plaques. Moreover, MAM can be functionally modulated by the amyloid-β peptide (Aβ). Based 
on evident alterations in mitochondrial function in AD, treatments enhancing mitochondrial 
resistance could be a promising strategy. The final study, Paper IV, concerned a potential novel 
drug, Dimebon (Latrepirdine), intended for treatment of AD. We found it to enhance 
mitochondrial function both in absence and presence of stress, and, in turn, partially protect cells 
to maintain cell viability. Since mitochondrial function is essential for synaptic integrity drugs 
targeting the mitochondria could have disease-modifying effect. 
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1 INTRODUCTION 
 
1.1 ALZHEIMER DISEASE 
Alzheimer disease (AD) is the most common form of dementia and affects millions of people 
worldwide. It is a complex, age-related, multifactorial disease affecting mainly the basal 
forebrain, cortex and hippocampus causing wide spread neurodegeneration, characteristic 
atrophy and enlargement of the ventricles (Wenk, 2003). Clinically, AD is characterized by 
gradual decline in memory and cognitive functioning, specifically planning, language, 
orientation, reasoning and performance of everyday activities, ultimately leading to death. At 
present there is no cure for AD and the drugs available on the market can only ameliorate 
symptoms. New technical advances have enabled researchers to study the disease in living 
patients and to investigate early events that occur before clinical symptoms are apparent. 
Presumably, the key to cure this devastating disease would be to diagnose it earlier and thereby 
enable treatment to be initiated much earlier than is the case today. Now treatment begins after 
symptoms are observed, though, by then, the patient already has wide spread pathology and 
neuronal loss. Still, the etiology of AD is largely unknown and there is a huge need for 
exploration of cellular pathways underlying the pathogenesis in the early phases in order to find 
promising, novel drug targets.  
 
Mitochondria play essential and diverse roles in the physiology of eukaryotic cells. Besides 
ATP production, mitochondria participate in numerous intermediate metabolic reactions and 
play a central role in calcium homeostasis, apoptosis, cell signaling, proliferation, and 
differentiation. Impairment of mitochondrial function has been implicated in a wide variety of 
human diseases, including neurodegenerative disorders (Seppet et al., 2009). This thesis will 
explore some cellular processes disturbed in AD with its focus on the aberrant caspase 
activation, increased intracellular production of amyloid β-peptide (Aβ) and the mitochondria-
associated endoplasmic reticulum (ER) membrane (MAM). The latter, a region, involved in 
regulating several pathways, including glucose, lipid metabolism, calcium homeostasis and 
apoptosis, all of which are altered in AD. Expanding knowledge about the mitochondria is 
important since mitochondrial abnormalities can play important roles in the etiology and 
progression of AD (Reddy and Beal, 2005). 
 
1.1.1 Neuropathology 
Molecular lesions arising from an accumulation of misfolded proteins in the aging brain are 
thought to cause oxidative and inflammatory damage, which in turn leads to energy failure 
and synaptic dysfunction. The neuropathological hallmarks of AD are characterized by 
extracellular neuritic plaques and intracellular neurofibrillary tangles (NFTs), which were 
first described in 1907 by Alois Alzheimer (Alzheimer et al., 1995). Not until 1980s were the 
main constituents of these lesions identified as Aβ and hyperphosphorylated tau, in plaques 
and NFTs, respectively (Masters et al., 1985; Grundke-Iqbal et al., 1986). At present, a 
definitive diagnosis of AD is made postmortem and includes neuropathological findings of 
plaques and NFTs. The pathological lesions are usually distributed in a characteristic way by 
which tau pathology is observed in the hippocampus and entorhinal cortex while prefrontal, 
parietal and temporal cortices exhibit most of the amyloid pathology (Braak and Braak, 
1991). Another prominent feature is inflammation as both microglial activation and 
astrocytosis are important mediators of the disease progression (Tuppo and Arias, 2005; 
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Town, 2010). The pathology affects mainly the cholinergic and the glutamatergic 
neurotransmitter systems. The cholinergic system, thought to be particularly vulnerable to 
aging, resides in the basal forebrain and is heavily involved in higher cognitive functions, 
such as, learning and memory. Loss of cells in both the nucleus basalis of Maynert and the 
medial septal nucleus projecting to neocortex and hippocampus, respectively, are prominent 
features of AD. Glutamate is a major transmitter in the brain and the transmitter of cortical 
and hippocampal pyramidal neurons. The formation of new memories, through the 
mechanism of long-term potentiation (LTP), involves glutamate and its receptors. In AD, 
histological studies indicate loss of pyramidal neurons and their synapses (Francis, 2003). 
The pathological change correlating most strongly with cognitive decline is synapse loss, 
thought to start in hippocampus and entorhinal cortex. Neurons depend heavily on 
mitochondria for energy supply, and also as modulators of signaling pathways that involve 
intracellular calcium along their profoundly polarized shape at distances far away from soma. 
Mitochondrial dysfunction is an early feature in AD that might be implicated in synaptic 
dysfunction. This will be discussed separately in the section below entitled “Mitochondria”.  
 
1.1.2 Pathophysiologic hypothesis  
It is generally believed that Aβ is important in the development of the neuropathic hallmarks of 
the disease, including: synapse loss, neurodegeneration, amyloid plaques, and neurofibrillary 
tangles (Hardy and Selkoe, 2002). This hypothesis is called the “amyloid hypothesis” and 
suggests that alteration in cleavage, processing and clearance of the amyloid precursor protein 
(APP) causes the pathogenesis of AD. This hypothesis has dominated the Alzheimer field as a 
pathophysiological explanation for about 20 years. This hypothesis has mainly survived as the 
top candidate due to the discovery of mutations causing familial AD (FAD) in the genes coding 
for amyloid precursor protein (APP) and presenilin 1 (PS1) and presenilin 2 (PS2), each of 
which influence production of Aβ. Nevertheless, this hypothesis has received criticism due 
weak correspondence between the amount of amyloid plaque and the observed progression of 
clinical symptoms. Therefore, this hypothesis was recently updated to “toxic Aβ oligomer 
hypothesis” as an attempt to explain the lack of correlation between plaque load and 
neurodegeneration and cognitive impairment (Benilova et al., 2012). Many other 
pathophysiological mechanisms have also been suggested. The oldest one is the “cholinergic 
hypothesis”, which is based on the relative selective loss of cholinergic neurons in nucleus 
basalis of Maynert (Bartus et al., 1982). The most commonly used drugs for treatment of AD, 
the acetylcholinesterase inhibitors (e.g. Donepezil, Tacrine and Galantamine), are targeted to 
compensate for the falling acetylcholine levels by reversibly blocking acetylcholine esterase. 
These drugs can only ameliorate symptoms and give modest improvements in memory and do 
not retard neurodegeneration.  
 
Another major theory today that correlates well with clinical symptoms is the “neuronal 
cytoskeletal degeneration hypothesis” which suggests that cytoskeletal changes that give rise 
to the formation of NFTs are the cause of the pathogenesis (Braak and Braak, 1991). 
Hyperphosphorylated tau, which comprises NFTs, is a microtubule-associated protein. Tau is 
primarily expressed in axons of the neurons and is important to stabilize microtubules during 
their assembly. Hyperphosphorylation results in decreased affinity for microtubules, which 
deteriorates axonal trafficking (Alonso et al., 1997; Iqbal et al., 2005). There are mutations in 
tau but none known to cause AD. Instead, such mutations, are linked to other neurodegenerative 
diseases like frontotemporal dementia (Foster et al., 1997). It has been suggested that 
hyperphosphorylation of tau might be triggered by Aβ accumulation. However, by what 
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mechanism Aβ affects tau is not fully clarified. One suggestion is that Aβ induces caspase 
cleavage of tau, since this truncation has been shown to proceed and be required for tangle 
formation (Hardy and Selkoe, 2002; de Calignon et al., 2010). 
 
Additional new hypotheses have emerged e.g. the “excitotoxicity hypothesis”, which suggests 
that glutamate toxicity could be one of the underlying pathogenic mechanisms of AD 
(Molinuevo et al., 2005). The drug, memantine, is a NMDA receptor antagonist and the latest 
of drugs approved by the U.S Food and Drug Administration (FDA) for treatment of AD. This 
drug is usually used in combination with acetylcholinesterase inhibitors in the later stages of the 
disease.  
 
Another is the “mitochondrial hypothesis” that postulates that age-related changes in 
mitochondria influence the susceptibility and vulnerability for environmental factors triggering 
AD pathology (Swerdlow et al., 2010). Aging mitochondria show increased production of 
reactive oxygen species (ROS) (Navarro and Boveris, 2007). Oxidative stress, in turn, leads to 
cellular lipid, protein and nucleic acid damage, eventually triggering apoptosis (Markesbery and 
Carney, 1999; Mattson, 2000). Accumulation of Aβ in the mitochondria has been detected in 
our laboratory as well as in other labs. Inside the mitochondria, Aβ disturbs essential 
mitochondrial functions leading to disturbances in energy production and induction of 
apoptosis. Recently, additional data supporting this hypothesis has emerged. Leuner et al. 
showed that oxidative stress, per se, triggers elevation of Aβ production to toxic levels, which 
in turn impairs the mitochondria, thereby initiating a vicious cycle that incorporates ROS and 
Aβ (Leuner et al., 2012). These events may indeed, be important in AD pathogenesis and may 
account for disturbed mitochondrial metabolism and synaptic dysfunction detected at early 
stages in the disease.  
   
The triggering events behind AD are still somewhat of a mystery and the heterogeneity of AD 
implies that there are probably several triggers. It is possible that all the above-mentioned 
hypotheses intervene with each other in a complex, hard-to-dissect manner. Nevertheless, Aβ 
probably has a central role in AD pathogenesis. However, with the many failures in drug 
development, which have mainly aimed to reduce Aβ levels, research has now tended to shift 
from mainly Aβ oriented to a wider, multi-candidate perspective. Other pathophysiological 
candidate areas for investigation that are being described today include hypometabolism, 
mitochondrial dysfunction, inflammation, dysfunctional autophagy, oxidative stress (NO), 
dysregulated calcium homeostasis, altered cholesterol and phospholipid metabolism. To 
understand what the triggers are, focus must be brought to pathophysiological events that 
precede Aβ aggregation and tau hyperphosphorylation. 
 
1.1.3 Genetics and risk factors 
Alzheimer disease is a multifactorial and heterogeneous disease where both genotype and 
environmental factors influence one’s susceptibility. Most of the AD cases are sporadic 
(without known genetic background) and only roughly 1% of the cases are autosomal-
dominantly inherited familial AD (FAD). Familial AD has been linked to mutations in three 
genes, including APP, located on chromosome 21; PSEN1 and PSEN2, located on 
chromosomes 14 and 1, respectively (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington 
et al., 1995). Most of the aggressive, early-onset forms of FAD are caused by mutations in the 
PSEN1 gene. The mutations in APP, PSEN1 and PSEN2 affect Aβ production in several ways, 
including increasing total Aβ or shifting the Aβ42/Aβ40 ratio by increasing the formation of the 
more aggregate-prone Aβ42 or decreasing the formation of Aβ40 (St George-Hyslop, 2000). 
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Presenilin mutations, apart from characteristic Aβ phenotypes, cause other biochemical 
changes, including: increased vulnerability to ER stress, disruption of intracellular calcium 
homeostasis, disruption of autophagy, disruption of neurotransmitter release and acceleration of 
the apoptotic processes (http://www.molgen.ua.ac.be/Admutation/) (Duff et al., 1996; 
Katayama et al., 2004; McCarthy, 2005; Thinakaran and Sisodia, 2006; Zatti et al., 2006; 
Miyoshi et al., 2009; Zhang et al., 2009; Lee et al., 2010; Parodi et al., 2010). 
 
The cause of sporadic AD is thought to be a combination of genotype and several 
environmental risk factors, making certain individuals more susceptible to develop AD. Several 
environmental factors are thought to play a role in predisposing people to develop AD, 
especially cardiovascular risk factors including midlife cholesterol levels and high blood 
pressure. Others are age, female gender, head trauma, cerebral infarct, oxidative stress, 
depression and diabetes mellitus type 2 (Munoz and Feldman, 2000; Veurink et al., 2003). 
Several genes have been found to associate with AD, including APOE, CLU, CR1, SORL1, 
PICALM and BIN1, however, the apolipoprotein E (APOE) gene remains the most strongly 
established risk factor for AD (Lambert and Amouyel, 2011). The APOE exists in three 
different alleles ε2, ε3 and ε4. Carriers of APOE ε4 have an increased risk (3-10 fold) of 
developing AD and as well as lowering the age of onset (Corder et al., 1993). APOE is a 
component of triglyceride-rich lipoprotein complexes carrying cholesterol and triglycerides 
between cells and in the blood. In the brain, APOE is thought to be particularly important since 
large lipoproteins do not pass the blood brain barrier (BBB) and the cholesterol metabolism is 
thought to be separated from the periphery. Twenty-five percent of the total cholesterol in the 
body resides in the brain. The cholesterol is produced mainly by the astrocytes and then 
transported by APOE to neurons and other cells in the brain. Cholesterol is an important 
building block for myelin, plasma membranes and lipid rafts, and thereby essential for brain 
plasticity and repair (Bjorkhem and Meaney, 2004). It has been suggested that lipid particles 
containing the ε4 allele contain less cholesterol and, thereby, deliver less cholesterol to the 
neurons as compared to the ε3 allele (Gong et al., 2002). APOE has also been associated with 
reduced clearance of Aβ since ε4 carriers often have an increased plaque load (Dolev and 
Michaelson, 2004). Moreover, ε4 carriers display increased hyperphosphorylation of tau, 
reduced glucose metabolism, exacerbation of medial temporal lobe atrophy, reduced fMRI 
activity and connectivity as well as greater loss of white matter (Pievani et al., 2011; Canu et 
al., 2012; Patil et al., 2012). The ε4 protein mediates potentially detrimental effects upon the 
mitochondria via the lipid- and receptor-binding regions, resulting in mitochondrial dysfunction 
and neurotoxicity (Chang et al., 2005; Chen et al., 2011). However, the exact 
pathophysiological mechanism associating isoform ε4 with increased AD-risk are still not clear. 
Other diseases, like cardiovascular disease and atherosclerosis, are also associated with the ε4 
allele (Verghese et al., 2011). APOE is located on chromosome 19 in a region of linkage 
disequilibrium (LD) that includes the genes: translocase of the outer mitochondrial membrane 
40 (TOMM40), apolipoprotein C1 (APOC1) and poliovirus receptor-related 2 (PVRL2). Recent 
genome-wide association studies report that the gene, TOMM40, is associated with AD (Roses 
et al., 2009; Shen et al., 2010). Several polymorphisms have been identified in TOMM40, 
though, which polymorphisms and in what manner each contributes to the disease is unknown. 
One of these polymorphism, a poly-T repeat, was studied in paper II and will be discussed 
further in the section entitled “Aβ inside the mitochondria” and in the “Results and Discussion” 
section below. 
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Interestingly, some factors decrease the risk of developing AD. For instance, a mutation in APP 
at the β-secretase cleavage site, which reduces BACE1 cleavage, thereby lowering the 
production of Aβ, has been found to protect against AD and cognitive decline in elderly 
(Jonsson et al., 2012) (for information about β-secretase cleavage, see the section “APP 
processing”). Furthermore, postmortem studies on 86-89 year-old individuals that regardless of 
profound accumulation of plaques and tangles in their brains had remained cognitively intact, 
point towards the mitochondria. The cognitively intact individuals showed preserved insulin 
response and no accumulation of Aβ in their mitochondria, unlike AD patients, who showed 
profound accumulation of Aβ oligomers and deranged insulin signaling (Taglialatela, Poster, 
AAIC, 2012, Vancouver, Canada). 
 
1.2 THE INVOLVEMENT OF CASPASES AND CELL DEATH IN AD 
 
1.2.1 Apoptosis 
Synaptic damage, neuronal network loss and cell death are processes giving rise to the 
characteristic brain atrophy seen in AD. Apoptosis has been implicated as the main cell death 
mechanism by which synapses degenerate and neurons are lost in AD (Stadelmann et al., 
1999a; Louneva et al., 2008a; Albrecht, S. et al., 2009). Caspases, a group of cysteine proteases 
cleaving after aspartyl residues, play an essential role in apoptosis. Upon activation, caspases 
target a broad spectrum of cellular proteins, ultimately leading to disassembly of the cell 
(Alnemri et al., 1996). In contrast to necrosis, apoptosis is strictly regulated and is characterized 
by several morphological and biochemical changes, including cell shrinkage, nuclear 
fragmentation, chromatin condensation, plasma membrane blebbing, exposure of 
phospatidylserine on the cell surface and, finally, engulfment by phagocytes. Regulation of the 
apoptotic process and equilibrium between cell division and apoptosis are essential for the 
organism. Disturbance can result in cancer or degenerative disease depending on either 
inappropriate suppression or activation of apoptosis. There are two main routes to initiate 
apoptosis, one involves stimulation of death receptors by external ligands (death receptor 
pathway) and one arises within the cell (mitochondrial pathway) activated by various forms of 
cellular stress such as oncogenes, DNA damage, hypoxia, oxidative stress, excitotoxicity or 
deprivation of survival factor (see Figure 1). 
 
Both these routes activate the caspase cascade. Based on their function, the size of their pro-
domain, homology in amino acid sequence and cleavage specificity, caspases can be divided 
into one inflammatory group (caspase-1, -4, -5, -11, -12, -13 and -14) and one group regulating 
apoptosis. Those regulating apoptosis are divided into two classes: initiator caspases (caspase -
2,-8, -9 and -10) and effector caspases (caspase-3,-6 and -7). These reside in the cells as 
zymogens (procaspases) and are activated post-translationally. The N-terminal contains the 
prodomain, which is required for activation. Caspase-2 and -9 contain the caspase recruitment 
domain (CARD) and caspase-8 and -10 contain the death effector domain (DED). The protein-
protein interactions between these two domains are involved in procaspase activation and 
downstream caspase activation. Mitochondria are central in apoptotic signaling, both by 
providing ATP that supports the high energy demanding events during apoptosis, and by 
releasing death proteins from the intramembrane space (e.g. cytochrome c, Omi/HtrA2, 
Smac/DIABLO) after the mitochondria permeability transitions pore (PTP) opening.  
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Figure 1: Apoptosis is induced by the extrinsic or the intrinsic pathway. The intrinsic pathway is 
initiated with outer mitochondria membrane permeabilization by upregulation of proapoptotic Bcl-2 
proteins (e.g. Bid and Bax), and by the repression of anti-apoptotic Bcl-2 protein and IAPs, which lead to 
release of apoptotic mediators e.g. Smac/DIABLO and cytochrome C. These factors activate the caspase 
cascade through caspase-9 leading to cell death. The extrinsic pathway is initiated by death ligands 
activating the caspase cascade through Caspase-2, -8 and -10 leading to caspase-3 activation and cell 
death.  
 
1.2.2 Caspases in healthy brain 
Caspase activation is not only involved in apoptosis but also in other processes including red 
blood cell development and microglia activation and as recently shown also in remodeling of 
dendrites, spines and synaptic connections in the healthy brain (Gilman and Mattson, 2002; 
Lamkanfi et al., 2007; Burguillos et al., 2011; Hyman, 2011). Caspase-3, earlier thought to be 
activated exclusively during apoptosis, can be activated in a transient fashion mediating 
neuronal plasticity, including: long-term depression (LTD), long-term potentiation (LTP), 
synaptic reorganization, and neurite retraction in the healthy brain without completion of the 
apoptotic program (Mattson et al., 1998; Gilman and Mattson, 2002; Gulyaeva et al., 2003; de 
Calignon et al., 2010; Li et al., 2010). Furthermore, caspase-3/7 and caspase-8 have been shown 
to regulate microglia activation, also without completion of the apoptotic program (Burguillos 
et al., 2011). Therefore, it is suggested that certain cell types (e.g. neurons and microglia) utilize 
apoptotic signaling pathways to regulate processes such as plasticity or activation. However, 
since aberrant caspase activation and apoptosis also have been linked to synaptic loss and 
neurodegeneration in AD (Mattson et al., 1998; Stadelmann et al., 1999b; Louneva et al., 
2008b) caspases must maintain activity in a transient fashion to hinder massive caspase 
activation and ultimate completion of the apoptotic program. Apoptosis might be restricted by 
trophic factors (Heerssen and Segal, 2002), cell adhesion proteins (Benson et al., 2000) and 
autophagy. In a rat model of subarachnoid hemorrhage, activation of autophagy was associated 
with neuroprotection against apoptosis by decreasing bax translocation to the mitochondria, 
thereby reducing early brain injury (Jing et al., 2012). Caspases are naturally controlled by 
various inhibitors such as the inhibitor of the apoptosis protein (IAP) family and Bcl-2 family 
proteins, which inhibit apoptosis by binding to active caspases. Eight members of the IAP 
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family have been described so far, including X-linked inhibitor of apoptosis (XIAP), neuronal 
apoptosis inhibitory protein (NAIP), survivin and livin. XIAP has dual functions, both as potent 
inhibitor of caspase activation and as an E3 ubiquitin ligase targeting caspases for degradation 
(O'Riordan et al., 2008). Currently, XIAP is the only caspase inhibitor known to inactivate 
active caspases (Eckelman et al., 2006). In AD, NIAP has been shown to be downregulated and 
XIAP to be upregulated (Christie et al., 2007). Such upregulation of XIAP might, 
unfortunately, not be sufficient to adequately regulate caspase activity in the AD brain since a 
significant amount of XIAP is inactivated by S-nitrosylation (SNO-XIAP). This inactivation, as 
reported recently, was caused by nitrosative stress inhibiting the E3 ligase and antiapoptotic 
activity of XIAP and, thereby, could play a role in causing aberrant caspase activation in AD 
(Nakamura et al., 2010). At present, the exact mechanism and factors that may be involved in 
keeping caspases active in a transient fashion are not fully understood. Increased understanding 
of the dysregulated apoptotic processes in AD would be important to gain therapeutic 
perspective on how to intervene and hinder aberrant caspase activation.  
 
1.2.3 Caspases in AD and their relationship to Aβ 
Several lines of evidence indicate excessive caspase activation in the AD brain. Activity of 
several caspases, especially caspase-3 and -6, has been demonstrated in both postmortem AD 
brains, postsynaptic densities in AD brains as well as in the cerebrospinal fluid of sporadic and 
FAD patients (Guo et al., 2004; Louneva et al., 2008b; Albrecht, P. et al., 2009; Albrecht, S. et 
al., 2009). Moreover, caspase activation and apoptosis have been linked to synaptic loss and 
neurodegeneration in human AD brain (Stadelmann et al., 1999a; Louneva et al., 2008a; 
Albrecht, S. et al., 2009; D'Amelio et al., 2011). Studies report that Aβ induces LTD in a 
caspase-3 dependent manner (Jo et al., 2011). Several lines of evidence suggest a correlation 
between caspase activation and elevated Aβ production (LeBlanc, 1995; Galli et al., 1998; 
Tesco et al., 2003; Takuma et al., 2005a; Cicconi et al., 2007; Xie et al., 2007). It has been 
suggested that caspases induce increased β-secretase cleavage of APP. This phenomenon can 
be explained by caspase-3 cleavage of GGA3, an adaptor protein involved in BACE trafficking, 
which thereby stabilize BACE (Tesco et al., 2007). Caspases cleave numerous other substrates, 
including the AD associated proteins APP, tau, PS1 and PS2. The cleavage of tau induces 
mitochondrial dysfunction and is required for tangle formation in vivo (Quintanilla et al., 2009; 
de Calignon et al., 2010). Caspase cleavage of APP generates two putative toxic peptides C31 
and Jcasp (Park et al., 2009). However, elevated Aβ production observed after caspase 
activation occurs independently of caspase cleavage of APP (Tesco et al., 2003). The role of 
PS1 and PS2 in apoptosis has been studied by several groups showing that PS1 and PS2 in most 
cases accelerate the apoptotic program (Wolozin et al., 1996; Alves da Costa et al., 2002; Alves 
da Costa et al., 2003; Fluhrer et al., 2004; Cai et al., 2006; Miyoshi et al., 2009). We have 
recently investigated caspase cleavage of PS1 and found that the elevation of the intracellular 
Aβ42/Aβ40 ratio can indeed partly be explained by the formation of γ-secretase complexes 
containing caspase cleaved PS1 (PS1caspCTF) as shown in Paper I. This will be further 
discussed under the subheading “The γ-secretase complex” and in section “Results and 
Discussion”. 
 
Axonal degeneration has been associated with caspase-6 activation. Caspase-6-knockout 
neurons have been shown to be protected against excitotoxicity, nerve growth factor 
deprivation and myelin-induced axonal degeneration (Uribe et al., 2012). However, caspase-6-
knockout mice display a hypoactive phenotype with learning deficits, thus indicating that 
caspase-6 activity is important for neuronal health. Caspase-6 activity must, however, be 
accurately regulated in order to hinder axonal degeneration (Uribe et al., 2012). Recently, a 
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ligand for death receptor 6 (DR6) was identified, which downstream activates caspase-6. 
Interestingly, it is the N-terminal fragment of APP, produced after β-secretase shedding (by 
BACE1 or meprin β), that binds to DR6 during trophic-factor deprivation and, thereby, induces 
caspase-6 dependent axonal degeneration (Nikolaev et al., 2009; Jefferson et al., 2011). Thus, 
transient caspase activity is important for several biological processes, implying that caution 
should be taken when considering caspase inhibition as a therapy for AD. Nevertheless, 
modulation might have positive results as demonstrated in the triple-transgenic AD mouse 
model lacking pathology when overexpressing anti-apoptotic protein Bcl-2 (Rohn et al., 2008). 
 
1.3 Aβ PRODUCTION, FUNCTION AND TOXICITY 
 
1.3.1 Amyloid precursor protein 
Amyloid precursor protein (APP) is an integral type I transmembrane protein with a long N-
terminal domain and short cytoplasmic C-terminal domain (see Figure 2). Two homologues to 
APP have been identified, including APP-like proteins 1 and 2 (APLP1 and APLP2), which 
share sequence similarity to APP, though lacking the Aβ part (Sprecher et al., 1993). Their 
function is not yet clarified but it has been proposed that the APP family members play a role in 
neurite outgrowth, synaptic plasticity, neuronal protein trafficking, transmembrane signal 
transduction, cell adhesion and neuronal survival (Mattson, 2004; Zheng and Koo, 2006; Zhang 
et al., 2012). Upon cell adhesion, APP together with other APP family members is thought to 
dimerize into homodimers or heterodimers in the process of cell adhesion (Soba et al., 2005). 
Double- and triple-knockout studies reveal that, while APP/APLP1-knockout mice survive, 
other combinations, including APP/APLP2, APLP1/APLP2 and APP/APLP1/APLP2 each 
individually show early postnatal lethality (Zhang et al., 2012), reduced number of synaptic 
vesicles and deteriorated presynaptic terminals at birth (Wang et al., 2005). When only 
knocking down APP, the mice show reduced brain and body weight, reduced grip strength, 
impaired spatial memory and LTP. This phenotype could be rescued in APP-N-terminal-part 
knock-in mice (Ring et al., 2007). Overexpression, on the other hand, results in the phenotype 
resembling Down syndrome (trisomy 21) and in premature death (Moechars et al., 1996). 
Overexpression is furthermore associated with degeneration of forebrain cholinergic neurons in 
a mouse model of Down syndrome due to decreased retrograde transport of nerve growth factor 
(Salehi et al., 2006). APP is ubiquitously expressed throughout the body and exists in three 
different isoforms 695, 751 and 770. The isoforms 751 and 770 express a Kunitz protease 
inhibitor (KPI) sequence in their N-terminal domain and are expressed in all cell types except 
neurons, which instead express the isoform 695. In neurons, the 695 isoform has been found 
localized to synapses both in post-synaptic densities and in adhesion complexes (Marotta et al., 
1992). In AD, a shift in APP isoform in neurons towards KPI-containing isoforms has been 
detected, a shift that is associated with increased Aβ production (Menendez-Gonzalez et al., 
2005; Bordji et al., 2010). Transportation of APP has been described to occur by fast moving (3 
µm/s) large tubules and vesicles out in the neurites by microtubules motors (Goldsbury et al., 
2006), and carried along axons to synaptic terminals (Lazarov et al., 2002). Many post-
translational modifications have been described in the ectodomain of APP, including N- and O-
glycosylation, sulfation and phosphorylation (Gandy et al., 1988; Weidemann et al., 1989; 
Hung and Selkoe, 1994). Upon phosphorylation at T668, APP has been shown to inhibit 
neuronal calcium oscillations (Santos et al., 2011). Furthermore, the ectodomain purportedly 
contains several different domains, including a growth factor-like domain; neuroprotective and 
neurotrophic domains; and copper-, zinc- and heparin-binding site domains (Chasseigneaux and 
Allinquant, 2012). Several ligands to APP have been suggested, including Aβ, F-spondin, and 
Netrin-1 (Lorenzo et al., 2000; Ho and Sudhof, 2004). APP is typically transported from ER 
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through the secretory pathway to the plasma membrane; however, in AD, APP is reported to 
also accumulate in the mitochondria (Anandatheerthavarada et al., 2003; Devi et al., 2006). 
APP contains a mitochondrial targeting signal at the N-terminal part consisting of at least the 
positively charged residues, 40, 44 and 51. Upon import into the mitochondria, APP is arrested 
at the acidic sequence 220-290, thereby causing APP to be stuck in the mitochondrial import 
pore, leaving a large C-terminal part (containing the Aβ region) outside in the cytoplasm (Devi 
et al., 2006). The accumulation of APP in the mitochondria hinders the import of other proteins 
and causes mitochondrial dysfunction and impaired energy metabolism (Anandatheerthavarada 
et al., 2003; Devi et al., 2006). Recently, the C-terminal part of APP was shown to become 
inserted into the OMM where it could be processed by mitochondrial γ-secretase complexes 
(Pavlov et al., 2011). Overexpression of APP has been shown to cause mitochondrial 
fragmentation and abnormal mitochondrial distribution, which was suggested to be caused by 
C99 or Aβ since the phenotype could be rescued by β-secretase inhibitors (Wang et al., 2008). 
Also Aβ and C99 have been observed to accumulate in the mitochondria at early points during 
disease course (Lustbader et al., 2004; Caspersen et al., 2005; Manczak et al., 2006; Hansson 
Petersen et al., 2008; Devi and Ohno, 2012). These data suggest that APP and its metabolites 
could, indeed, play an active role causing mitochondrial dysfunction. The accumulation of Aβ 
inside the mitochondria will be discussed further under the subheading “Aβ inside the 
mitochondria”.  
 
1.3.2 APP processing 
APP is processed through two pathways: the non-amyloidogenic and the amyloidogenic 
pathways (see Figure 2), the latter of which accounts for generation of Aβ through sequential 
cleavage by β- and γ-secretase. The enzymes that are thought to serve as β-secretases, include 
membrane-bound aspartyl proteases; and so far BACE1 has been described as the main one. 
However, cathepsin B and Meprin β have also been suggested (Vassar, 2004; Cole and Vassar, 
2007; Jefferson et al., 2011; Hook et al., 2012; Kindy et al., 2012). The cleavage of APP by β-
secretase generates two fragments: one extracellularly released soluble ectodomain (sAPPβ) 
and one membrane-anchored fragment (C99). The subsequent γ-secretase processing of C99 
results in the generation of Aβ and the APP intracellular domain (AICD) (see Figure 2). γ-
Secretase determines the C-terminal of Aβ through sequential cleavage of C99, generating tri- 
and tetra-peptides from the C99 stub. There are two proposed alternative cleavage-pathways 
starting at the ε-site that releases AICD and generates either Aβ48 or Aβ49. The subsequent 
shortening of Aβ48 and Aβ49 are made by carboxypeptidase-like γ-cleavages where Aβ49 are 
further processed to Aβ46>Aβ43>Aβ40, and Aβ48 gives rise to Aβ45>Aβ42>Aβ38 (Takami et 
al., 2009; Chavez-Gutierrez et al., 2012). The shortening of the long Aβ decreases the 
hydrophobicity and increases the probability for it to be released from the membrane. It has 
been shown that the first cleavage at the ε-site determines which of the two cleavage-pathways 
will be chosen in vivo (Funamoto et al., 2004). FAD mutations are thought to have already 
affected the ε-site cleavage site, causing a shift towards the Aβ48 production lineage (Chavez-
Gutierrez et al., 2012; Golde et al., 2012). 
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Figure 2. APP processing. APP is processed either by the amyloidogenic pathway by the β- and γ-
secretases or by the non-amyloidogenic pathway by α- and γ-secretases. β-secretase cleavage generates 
C99 that is further processed to Aβ and AICD. α-Secretase cleavage generates C83 which gives rise to p3 
and AICD.   
 
The non-amyloidogenic pathway involves cleavage by α-secretase (ADAM10 and ADAM17), 
which belong to the zinc protease super family (Allinson et al., 2003; Vincent and Govitrapong, 
2011) and by γ-secretases. The α-secretase cleaves APP within its Aβ peptide sequence, 
preventing its production, while generating a longer soluble ectodomain (sAPPα) and one 
membrane-anchored fragment (C83). The subsequent γ-secretase processing of C83 results in 
the generation of p3 and the APP intracellular domain (AICD) (see Figure 2). The biological 
functions of the cleavage products are not fully known, but AICD is thought to translocate to 
the nucleus where it is involved in transcriptional regulation of different genes (e.g. APP, GSK-
3β, KAI1, neprilysin, BACE1, EGFR and LRP1) including genes involved in apoptosis (p53) 
(Cao and Sudhof, 2004; Kerr and Small, 2005; Pardossi-Piquard et al., 2005; Zhang et al., 
2011). AICD also modulates cellular calcium homeostasis and ATP content (Hamid et al., 
2007). The physiological role of sAPPα, which differ by only 16 amino acids at its C-terminus 
as compared to sAPPβ, is purportedly neuroprotective and is far more potent in regulating 
neuronal activity (Barger and Mattson, 1996; Turner et al., 2003; Turner et al., 2007; Taylor et 
al., 2008). The products of the amyloidogenic pathway, sAPPβ and C99, have been proposed to 
possess opposite functions, that is, they activate cell death pathways and cause synaptic and 
memory deficits (Nikolaev et al., 2009; Tamayev et al., 2012). However, recently, both sAPPα 
and sAPPβ have been shown to regulate the proliferation and differentiation of neuronal 
precursor cells deriving from the subgranular zone of the rat hippocampus (Baratchi et al., 
2012). Thus, today, the whole understanding of APP metabolites and their role in AD 
pathogenesis is lacking.  
 
The fate of APP depends on trafficking within the cell. Sortilin-1, a newly discovered risk 
factor for AD, directs the trafficking of APP from the plasma membrane into the cell were it 
can be processed by BACE1, preferably in intracellular compartments (Rogaeva et al., 2007). 
BACE1 has been found along the secretory pathway including trans-Golgi network, endosomes 
and lysosomes and exhibit its highest activity at acidic pH (Cole and Vassar, 2007). In the 
brain, BACE1 is heavily expressed in axons and presynaptic terminals of the mossy fiber 
pathway as well as in the amygdala (Vassar et al., 2009). In sporadic AD patients, BACE1 
expression level and activity have been found to be elevated (Yang et al., 2003). This elevation 
could in some cases be explained by a defect in a microRNA controlling BACE1 expression 
(Hebert et al., 2008). Apoptotic processes and Aβ have also been suggested to elevate BACE1 
expression levels (Xie et al., 2007; Sadleir and Vassar, 2012). BACE1-knockout mice exhibit 
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hypomyelination and altered neurological behaviors such as reduced grip strength and elevated 
pain sensitivity (Laird et al., 2005; Hu et al., 2006; Willem et al., 2006; Gersbacher et al., 2010). 
Inhibition of BACE causes side effects, including: schizophrenic symptoms, increased 
mortality, epileptic seizures, hyperactivity, anxiety and impaired axon guidance, probably due 
to the lack of cleavage of its other substrates including neuregulin 1, seizure-protein 6, L1, 
CHL1 and contactin-2 (Kuhn et al., 2012). The α-secretase, apart from cleaving APP, is 
implicated in the control of cytokine and growth-factor shedding at the plasma membrane e.g. 
Notch, tumor necrosis factor-α and epidermal growth factor. This enzyme acts primarily at the 
plasma membrane where the cleavage of its substrates, including APP, takes place (Zhang et 
al., 2012). The γ-secretase complex will be discussed separately under the subheading “The γ-
secretase complex”.  
 
1.3.3 The amyloid β-peptide (Aβ) 
In FAD, the mutations in APP, PS1 or PS2 are thought to increase the Aβ42/Aβ40 ratio. In 
sporadic AD, several events have been shown to increase Aβ production, e.g. ROS production 
or decreased expression of Aβ-degrading enzymes, including insulin-degrading enzyme (IDE), 
neprilysin, cathepsin B and PreP (Miners et al., 2008; Alikhani et al., 2011; Leuner et al., 2012). 
The biophysical and biochemical properties of Aβ vary according to its length, the longer are 
more prone to aggregate. The two main forms are Aβ40 and Aβ42, the latter of which is the 
main constituent of amyloid plaques. Also Aβ43 has been detected in plaques (McGowan et al., 
2005; Welander et al., 2009). Despite the difference in only two and three amino acids, Aβ42 
and Aβ43 are more hydrophobic and their aggregation potential is much higher than that of 
Aβ40. Several research groups have demonstrated that the relative level of Aβ42 in relationship 
to Aβ40 is critical for the pathogenesis of the disease, suggesting a central role of Aβ42 in the 
development of AD. Even a minor increase in the Aβ42/Aβ40 ratio induces formation of toxic 
oligomers, signifying that Aβ40-monomers could prevent aggregation and toxicity of Aβ42 
(Yan and Wang, 2007; Jan et al., 2008; Kuperstein et al., 2010). Studies even suggest that such 
minor changes of Aβ42 or Aβ43 might trigger a pathogenic cascade and drive the seeding of 
plaques (Masters and Selkoe, 2012). What drives the transition from normal Aβ production to a 
pathological state is not fully understood. The complexity of Aβ peptides has become greater 
still, with the identification of several other enzymatic processes that are involved in modifying 
the Aβ pool. For example, Aβ peptides can further be modified by aminopeptidase, 
glutaminylcyclase or isomerase, each generating N-terminally truncated peptides. Further 
modification by phosphorylation and pyroglutamate reactions result in a mix of more than 20 
Aβ variants (De Strooper, 2010; Portelius et al., 2011; Benilova et al., 2012). These might 
participate differently in normal brain or in oligomerization and fibrillization in AD-afflicted 
brain. The dominant hypothesis articulating of which Aβ species are most toxic points toward 
the soluble oligomers that exist between monomeric Aβ and the amyloid Aβ fibrils in the 
plaques. Whether the polymerization of Aβ occurs intracellularly or extracellularly is not clear. 
Some studies claim that it mainly occurs in intracellular compartments, in particular, 
endosomes or lysosomes, where the concentration of Aβ-peptides can be enriched and where 
the low pH has the capacity to promote the oligomerization. When these are later secreted they 
become potential seeds for extracellular plaques (Hu et al., 2009). Moreover, Aβ is mainly 
thought to exert its toxicity intracellularly. More evidence for this was recently found in a study 
of an autophagy-deficient mouse crossed with a tgAPP mouse. Deficiency in autophagy leads 
to intracellular Aβ accumulation and severe cognitive deficits. This finding implicates 
intracellular Aβ as being cytotoxic, thus accounting for its protective role as it, consequently, is 
secreted into extracellular space (Nilsson, Poster, AAIC, 2012, Vancouver, Canada). 
 12 
 
The physiological role of Aβ is not known, but since it normally is continuously and abundantly 
produced already from embryogenesis, it might not be associated only with neurotoxicity. For 
instance, Aβ at low concentrations has been shown to be neuroprotective, enhancing the 
survival of neurons, and to have neurotrophic properties stimulating neuronal (Aβ40) or 
astrocytic (Aβ42) cell fate of primary neural progenitor cells (Chen and Dong, 2009; Giuffrida 
et al., 2009). Activity-dependent co-secretion of Aβ, together with neurotransmitters, suggests 
that Aβ acts as a modulator at the synapse. Aβ depresses excitatory synaptic transmission 
inhibiting LTP. Therefore Aβ might participate in negative feedback regulating neuronal 
activity (Hsieh et al., 2006; Hook et al., 2012). Such co-secretion has been found from dense 
core secretory vesicles containing a variety of neurotransmitters including catecholamine, 
dopamine, norepinephrine and neuropeptides (Hook et al., 2012). Furthermore, Aβ may have a 
biological role in lipid metabolism, demonstrating a capacity to reduce synthesis of both 
cholesterol and sphingomyelin (Grimm et al., 2005). Thus, the production of Aβ might be of 
physiological importance in the central nervous system. However, dysregulated production, 
impaired secretion from cells, intracellular accumulation or defective clearance from the brain 
probably play fundamental roles in the pathophysiology of AD. 
 
1.3.4 The γ-secretase complex 
γ-Secretase is a multi-protein complex consisting of at least four subunits: PS1 or PS2, 
Nicastrin, anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2) (see Figure 
3).  
 
 
 
Figure 3. Illustration of the γ-secretase complex. It consists of at least Pen2, PS, Nicastrin (Nct) and Aph-
1. PS undergoes endoproteolysis generating a N-terminal fragment (NTF) and a C-terminal fragment 
(CTF). The CTF can later be cleaved by caspases in the large cytosolic loop. The active site in PS is 
shown by asterisks. 
 
The assembly of the four subunits takes place within the endoplasmic reticulum (ER) where the 
γ-secretase complex remains until it is fully assembled (Capell et al., 2005). Membrane protein 
folding is carefully supervised by the quality control (consisting of e.g. chaperones) within the 
ER ensuring that misfolded proteins do not leave the ER. Initially, Aph-1 and Nicastrin are 
assembled together before the remaining components are added (Takasugi et al., 2003). The 
addition of Pen-2 is thought to result in a conformational change in Nicastrin that promotes 
endoproteolysis of presenilin (Takasugi et al., 2003). Presenilin undergoes endoproteolytic 
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cleavage in the large cytosolic loop (Ala299) generating N- and C-terminal fragments (NTF and 
CTF). The two fragments form a heterodimer within the γ-secretase complex harboring the two 
highly conserved aspartic acid residues, D257 and D385 in the six and seven transmembrane 
domains, which form the active site. PS is a multi-membrane-spanning protein with 9 
transmembrane regions that, after endoproteolysis in the large cytosolic loop, are separated into 
NFT and CTF containing 6 and 3 transmembrane regions, respectively (see Figure 3). The CTF 
contains most of the large cytosolic loop, which is involved in regulating the enzymatic activity 
of the γ-secretase complex at the γ-cleavage site thereby adjusting Aβ species formed (Deng et 
al., 2006). This can, for example, be seen in cell lines on a PS-deficient background, and in the 
absence of the entire loop in the PS1Δexon10 mouse model. These mice exhibit a great 
reduction of Aβ40, though Aβ42 level is unchanged, which is accompanied by exacerbation of 
plaque pathology (Deng et al., 2006; Wanngren et al., 2010). Allosteric changes in PS1 
conformation have been shown to underlie changes in the Aβ42/Aβ40 ratio (Uemura et al., 
2009). This is the case for the FAD mutations in PS1, which cause closer conformation of the γ-
secretase complex, favoring the Aβ42 production linage (Uemura et al., 2009). Caspases can 
cleave PS1 in the CTF-part at Asp333 and Asp345, generating a ∼12 kDa C-terminal fragment 
that is missing a large part of the loop domain (Kim et al., 1997; Grunberg et al., 1998). In our 
laboratory, it has previously been shown that caspase-cleaved PS1CTF (caspCTF), despite the 
truncation in the large cytosolic loop, forms active γ-secretase complexes in cells exposed to 
apoptotic stimuli (Hansson et al., 2006). As we show in Paper I, this truncation increases the 
intracellular Aβ42/Aβ40 ratio and could, therefore, partly account for the elevated Aβ 
production seen during caspase activation. This finding is further discussed in the section 
“Results and Discussion”. Animal studies have shown that PS1 is essential for embryonic 
development. PS1 double-knockout is lethal compared to PS2 double-knockout mice that are 
phenotypically normal (Donoviel et al., 1999; Handler et al., 2000). Furthermore, mice lacking 
both PS1 and PS2 in the postnatal forebrain exhibit reduced long-term memory formation and 
shortened neuronal survival, inducing neurodegeneration and memory loss, whereas, mouse 
models overexpressing Aβ have failed to produce the characteristic AD phenotype (Saura et al., 
2005; Shen and Kelleher, 2007). 
 
γ-Secretase is thought to work as an aspartyl-protease with its catalytic activity located inside 
the lipid bilayer through a process called regulated intramembrane proteolysis (RIP) (Selkoe 
and Kopan, 2003). The activity of the γ-secretase complex can be modulated by interacting 
proteins, for example, CD147, TMP21, GPR3 and γ-secretase activating protein (GSAP), which 
are suggested to thereby regulate Aβ production (Zhou et al., 2005; Chen et al., 2006; Thathiah 
et al., 2009; He et al., 2010). New proteins that modulate the γ-secretase activity are identified 
frequently. For instance, two mitochondrial proteins that associate with the γ-secretase and 
affect Aβ production have recently been reported, including NADH dehydrogenase 
(ubiquinone) iron-sulfur protein 7 (NDUFS7) and voltage-dependent anion-selective channel 
(VDAC1) (Frykman et al., 2012; Hur et al., 2012). NDUFS7 is the core subunit of complex I in 
the electron transport chain in the inner mitochondrial membrane and VDAC1 is an ion channel 
located at the outer mitochondrial membrane. Another is Erlin-2, which resides in lipid raft like 
regions on ER (Teranishi et al., 2012). 
 
The γ-secretase complex cleaves type 1 transmembrane proteins. New substrates for the γ-
secretase complex are frequently being discovered. To date, more than 90 have been described, 
including Notch (signaling receptor cell, fate decisions during embryonic development, neuritic 
growth), CD44 (cell adhesion), E/N-cadherin (cell adhesion), p75NTR (neurotrophin co-
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receptor), ErbB-4 (growth-factor-dependent receptor tyrosine kinase), and insulin receptor 
(glucose metabolism), to name a few (Lleo and Saura, 2011).  
 
The γ-secretase complexes are described as being localized in various compartments of the cell, 
including: ER/Golgi (De Strooper et al., 1997), nuclear envelope (Kimura et al., 2001), 
endosomes (Vetrivel et al., 2004), lysosomes (Pasternak et al., 2003), mitochondria (Hansson et 
al., 2004), plasma membrane (Tarassishin et al., 2004), synaptic vesicles (Frykman et al., 2010) 
and intercellular contacts known as adherens junctions (Marambaud et al., 2002). γ-Secretase 
activity is enriched in lipid rafts, which are specialized regions in cellular membranes situated 
in plasma membrane or intracellular compartments such as the mitochondria-associated ER 
membrane (MAM) (Urano et al., 2005; Hur et al., 2008; Area-Gomez et al., 2009). 
Interestingly, one recent study implies that the γ-secretase complex has its highest activity at 
MAM (Area-Gomez et al., 2009), a highly specialized subregion in ER that enables close 
contact with the mitochondria. MAM will be discussed separately under the subheading 
“Mitochondria-associated ER membrane”.  
 
Therapeutics aimed at inhibiting γ-secretase activity have been associated with severe side 
effects, probably due to suppression of cleavage of the other substrates, especially Notch. 
Therefore, γ-secretase modulators (GSMs) that selectively reduce Aβ production without 
affecting the other substrates are potentially safer, leading this class to currently be investigated 
(Tomita, 2009). The GSMs exert their mode of action by binding to either APP or the subunits 
of the γ-secretase complex, while PS is thought to be the primary target (Jumpertz et al., 2012).  
 
Some researchers postulate that PSs possess other functions apart from being a component in 
the γ-secretase complex, including regulating calcium homeostasis, autophagy and 
neurotransmitter release (Zhang et al., 2009; Lee et al., 2010; Zhang et al., 2010). FAD 
mutations in PS result in deranged calcium signaling and several reports have indicated that 
associated neuronal calcium disruptions are early events in AD pathogenesis. Studies of 
fibroblasts lend support to this description, showing that abnormally high amounts of calcium 
are detected upon inositol-1,4,5-triphosphate (IP3) stimulation (Ito et al., 1994). Similar results 
were obtained in studies on cortical and hippocampal neurons from PS FAD mutant knock-in 
mice (Chan et al., 2000). Several explanations to this phenomenon have been postulated, 
including that PS affects various calcium channels (e.g. ryanodine receptors, IP3R and SERCA 
pump) and/or functions as a passive ER calcium leak channel controlling the steady state of 
calcium in ER (Tu et al., 2006; Zhang et al., 2010). In the case of FAD mutations in PS, these 
functions are disrupted and the loss of such leak function has been postulated to cause ER 
calcium overload (Zhang et al., 2010). Furthermore, a new function of PS2 has been described 
that involves regulating ER-to-mitochondria calcium fluxes at the MAM (Zampese et al., 
2011). 
 
In autophagy, PS has a fundamental role in targeting v-ATPase to lysosomes, promoting 
lysosomal acidification and proteolysis during autophagy (Lee et al., 2010). Autophagy is 
needed for proper degradation of proteins and organelles including the mitochondria. Defective 
lysosomal proteolysis causes pathogenic protein accumulation and defective mitochondrial 
turnover, which, indeed, could be implicated in AD pathogenesis. Moreover, defective 
autophagy has been associated with increased PS expression and γ-secretase activity (Ohta et 
al., 2010). Thus, it might be important to consider other biological roles of both PS and APP 
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apart from their involvement in Aβ generation in order to understand the disease mechanisms 
behind both FAD and sporadic AD.   
 
1.4 MITOCHONDRIA 
 
1.4.1 Mitochondria: more than just a powerhouse 
Mitochondria are cytoplasmic organelles originating from invading bacteria 1.5 billion years 
ago (Wallace, 1982). Some features remain reflecting this origin like double-membrane 
structures and a circular genome with mitochondrial-specific transcription, translation and 
protein assembly systems. To adapt to its new environment the mitochondria has reduced its 
genome to about 16 500 bp encoding 13 polypeptide, 2 mRNA and 22 tRNA genes. Thus, 
several essential mitochondrial genes have been transferred to the nucleus and approximately 
1000 proteins are translated by free ribosomes in the cytosol and then imported into the 
mitochondria (Schatz, 1996). 
 
 
Figure 4. Overview of mitochondria and oxidative phosphorylation. (A) Glucose is metabolized via 
glycolysis to pyruvate, which enters the mitochondria and converts into Acetyl-CoA, which is used for 
driving the tricarboxylic acid cycle (TCA) and, subsequently, oxidative phosphorylation (OXPHOS) 
where ATP is produced. OMM (outer mitochondrial membrane), IMS (intermembrane space) IMM 
(inner mitochondrial membrane). (B) OXPHOS is conducted by the electron transport chain. The transfer 
of electron from the donors (NADH and succinate) to the acceptor (O2) is coupled to proton transfer 
producing the electrochemical potential, which is used in complex V to produce ATP.  
 
The import machinery consists of TOM and TIM complexes forming pores in the outer 
mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM), respectively. The 
OMM is highly permeable to low-molecular-weight substances. While the IMM provides a 
barrier through which ions have to be actively transported via specific channels. The IMM 
houses the electron transport chain complexes (complex I-IV and the ATP synthase) 
responsible for ATP production via oxidative phosphorylation (OXPHOS) (see Figure 4A). At 
complex I, III and IV, protons are pumped across the IMM into the intermembrane space (IMS) 
creating the mitochondrial membrane potential (ΔΨm). This electrochemical gradient is crucial 
for maintaining cellular viability since OXPHOS rely on the energy content of it (see Figure 
4B). The brain accounts for only 2% of the body mass but is responsible for 20% of the oxygen 
consumption via OXPHOS (Papa, 1996). The matrix of mitochondria, house enzymes in the 
tricarboxylic acid cycle (TCA) and enzymes used to conduct beta-oxidation.  
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Mitochondria form highly dynamic tubules that continuously fuse and divide so as to control 
correct distribution, morphology and quality of the mitochondrial pool. The central components 
that mediate mitochondrial dynamics are the fusion proteins: mitofusin1, mitofusin 2 (Mfn1 and 
Mfn2) and optic atrophy type 1 (Opa1) and the fission protein, dynamin related protein 1 
(Drp1) (Chan, 2006). As described above, mitochondria are key regulators of cell survival and 
death. Dysfunction of mitochondria leads to insufficient energy metabolism, reduced ATP 
production, impaired calcium buffering and increased generation of reactive oxygen species 
(ROS) (Beal, 2005). Neurons are metabolically active cells that consume a lot of energy at 
locations distant from the cell body. As a result, these cells are particularly dependent on 
mitochondrial function for energy conversion. Normally, cells contain a mix of healthy and 
defect mitochondria (heteroplasmy). As we age, the mitochondria pool weakens mainly due to 
oxidative insult to proteins, lipids and nucleic acids, which is also implicated in driving the 
aging process (Muller et al., 2010). Mitochondrial turnover via autophagy and fusion/fisson is 
of great importance as this serves to maintain a healthy cellular pool of mitochondria, especially 
in post mitotic cells like neurons, where the mitochondrial pool cannot be renewed and limited 
replacement of damaged cells occur. Since aging is the main risk factor for sporadic AD and 
mitochondrial dysfunction is implicated in the aging process a role of mitochondria in sporadic 
AD has been suggested (Reddy, 2007). 
  
1.4.2 Mitochondrial dysfunction in neurons 
Several lines of evidence implicate that Aβ exerts its toxicity intracellularly (Wilson et al., 
1999; Gouras et al., 2000; Wirths et al., 2004; Aoki et al., 2008) and mitochondria are suspected 
to have a role in it. Neurons are vulnerable to oxidative insult since they have a high rate of 
energy and oxygen utilization, poor concentration of classical antioxidants, high levels of 
redox-active metals and high content of polyunsaturated lipids. Damage to mitochondria in 
neurons is detrimental since there is limited or no regeneration/replacement capacity of neurons 
in the brain. Mitochondria are the major source and target of oxidative stress. Reactive 
oxidative species (ROS) is produced during OXPHOS when electrons passing through the 
electron transport chain and some electrons leak out at complex I and complex III. These can 
react with oxygen and yield superoxide anions (.O2-), which then can be converted to hydrogen 
peroxide (H2O2) by superoxide dismutase (SOD). The presence of Fe2+ accelerates the 
decomposition of H2O2 to hydroxyl radicals (.OH), and nitric oxide (NO.) reacts with .O2- to 
produce peroxynitrite (ONOO.). The mitochondria are particularly susceptible to oxidative 
damage. Mitochondrial DNA has a mutation rate estimated to be 10 to 20 times higher than that 
of nuclear DNA. This sensitivity is due to the lack of protective histones and limited, available 
repair mechanisms (Brown et al., 1979). For protection, IMM incorporates a number of free 
radical scavengers, such as vitamin E, ascorbate, catalase and glutathione. There is also 
enzymatic removal of free radicals by manganese superoxide dismutase (MnSOD) in the 
mitochondria and by SOD in the cytoplasm. All 13 genes coding for proteins in the 
mitochondrial genome are essential for execution of normal OXPHOS (Manczak et al., 2005). 
Complex I is especially susceptible to the aging process since 7 of the 13 genes encoded in the 
mitochondrial genome code for subunits belonging to complex I. Therefore, complex I 
deficiency is commonly observed during aging and can trigger neurodegeneration (Abramov et 
al., 2010). Interestingly, recently, deficiency of complex I and III accompanied with ROS 
production was shown to be sufficient to induce increased production of Aβ, which in turn 
triggered a vicious cycle of mitochondrial dysfunction more ROS and Aβ production (Leuner et 
al., 2012). The triggering event for altered APP processing in sporadic AD is unknown; though 
hypothetically, this vicious cycle might explain some of the events leading to elevated Aβ 
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production. This is supported by other studies that found that H2O2 and ROS elevate Aβ levels 
in cells and mouse models (Sun et al., 2006). Several recent findings show that mitochondrial 
dysfunction is one of the earliest events in AD (Hauptmann et al., 2009; Rhein et al., 2009; Du 
et al., 2010). Aβ has been detected inside mitochondria in postmortem AD brains, in transgenic 
mice overexpressing mutant APP and in human brain biopsies from patients with amyloidosis, 
as well as in neurons exposed to fluorescent Aβ in vitro (Lustbader et al., 2004; Caspersen et 
al., 2005; Hansson Petersen et al., 2008). As described earlier, cognitively intact individuals 
with profound accumulation of plaques and tangles in their brains could be discriminated from 
individuals with AD based on absence of Aβ accumulation in their mitochondria (Taglialatela, 
Poster, AAIC, 2012, Vancouver, Canada). 
 
Early in the pathogenesis, a reduced number of mitochondria is observed in affected neurons 
(Hirai et al., 2001), brain glucose metabolism is decreased (Mosconi, 2005), the activities of 
both tricarboxylic acid (TCA) cycle enzymes (Bubber et al., 2005) and cytochrome c oxidase 
are reduced (Parker et al., 1990; Kish et al., 1992; Parker and Parks, 1995; Cardoso et al., 2004) 
and mitochondrial gene expression is upregulated perhaps as a compensatory mechanism 
(Reddy et al., 2004). Furthermore, maternal family history of AD predisposes to reduced brain 
glucose metabolism (Mosconi et al., 2007). Mitochondrial Aβ accumulation has been shown to 
occur prior to plaque formation in tgAPP mice, indicating that this is an early event in AD’s 
pathogenesis (Caspersen et al., 2005). Recent findings imply that protein modifications, 
including carbonyl, 3-nitrotyrosin, 4-hydroxy nonenal (HNE), and S-glutathionyl, could 
regulate the activity of the metabolic enzymes. Many of these modifications result in significant 
inhibition of enzyme activity and, therefore, are likely to be involved in the dysregulation of 
metabolic pathways in AD (Hedskog et al., 2012). Neurons can utilize glucose, lactate, and 
ketone bodies as energy sources (Izumi et al., 1998; Suzuki et al., 2011). OXPHOS is the main 
pathway used for energy production in the brain since 15 times more energy is produced from 
respiration as compared to glycolysis. Cellular energy production is highly regulated. The 
activities of glycolysis, TCA, and respiration are integrated via feedback, including inhibitory, 
via ATP (Pasteur effect) and citrate controlling the rate of glycolysis. From the blood, glucose 
is transported over the BBB (endothelial cells and astrocytes) via GLUT1 transporter and 
subsequently transported into neurons via GLUT3. During hypometabolism (as is the case in 
AD brain), the brain cells compensate by increasing the activity of glycolytic proteins, called 
the Warburg effect, to override transient energy deficits and hypoxic environment (Hedskog et 
al., 2012). Recently, neuronal cells that utilize the Warburg effect were shown to be resistant to 
Aβ toxicity (Newington et al., 2011). Although, recent data from Suzuki and colleagues show 
that glycolysis is not enough for neuronal viability and survival in the long run (Suzuki et al., 
2011). This study emphasizes the importance of lactate in synaptic plasticity. Lactate is 
produced by astrocytes (from glucose or glycogen metabolism) and transported to the neurons 
via monocarboxylate transporters. The inhibition of these channels, either on the astrocyte or 
neuronal side, causes impairment of LTP, substantiating the importance of a functional 
oxidative metabolism for neuronal plasticity (Suzuki et al., 2011). It is possible that the shift 
from OXPHOS to glycolysis that occurs in AD neurons can temporally provide enough ATP to 
sustain neuronal function. However, for the formation of LTP and other energy demanding 
processes a decreased glucose uptake in AD brain in combination with dysfunctional 
mitochondria may eventually result in synaptic failure and neuronal loss. 
Abnormal mitochondrial structure (Baloyannis, 2006) and impaired balance of mitochondrial 
fusion and fission are found in the AD brain and in AD-animal models (Knott et al., 2008; 
Wang et al., 2009; Trushina et al., 2012). Exposure of neuronal cells in culture to conditioned 
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medium from cells stably expressing mutant forms of APP, or exposure to synthetic Aβ, 
induces mitochondrial fragmentation and abnormal distribution, which results in mitochondrial 
fission, loss of dendritic spines, and eventually cell death (Rui et al., 2006; Wang et al., 2008). 
Also, autophagic degradation of mitochondria may be dysfunctional in AD. Lysosomal 
proteolysis and autophagy require PS1, and AD-related PS1 mutations disrupt this degradation 
pathway (Lee et al., 2010). Despite the evident alteration in mitochondrial dynamics and 
metabolism in AD, the underlying mechanisms are unclear. It could result from environmental 
toxin, Aβ accumulation or acquired or inherited nuclear DNA and mtDNA mutations. 
 
1.4.3 Aβ inside the mitochondria 
Inside mitochondria, Aβ could interact with several proteins including complex IV in the 
electron transport chain (Rhein et al., 2009), Aβ-binding alcohol dehydrogenase (ABAD) 
(Lustbader et al., 2004), cyclophilin D (CypD) (Du et al., 2008) and the mitochondrial DNA 
base excision repair (BER) system (Taglialatela, Poster, AAIC, 2012, Vancouver, Canada) (see 
Figure 5).  
 
 
Figure 5. Illustration of Aβ inside the mitochondria. Inside the mitochondria Aβ can cause damage 
through interactions to various proteins including the mtDNA repair system (BER), complex IV in the 
electron transport chain (ETC), ABAD, and cypD causing PTP opening.   
 
The binding to complex IV impairs OXPHOS and thereby the energy production, reducing the 
formation of ATP. ABAD is localized to the mitochondrial matrix and belongs to the short 
chain dehydrogenase reductase family. It has an essential physiological role in the metabolism 
of e.g. n-isopropanol, β-estradiol and keton body α-3-hydroxybutyrate and its activity is 
important to protect against metabolic stresses caused by, for example, ischemia (Du Yan et al., 
2000). Inactivation of its counterpart (scully) in Drosophila results in a lethal phenotype with 
multiple developmental abnormalities. The binding of Aβ to ABAD is thought to disturb its 
normal function and cause mitochondrial dysfunction, increased ROS production and cell death 
(Takuma et al., 2005b). Inhibition of the interaction between Aβ and ABAD improves 
mitochondrial function in a mouse model of AD (Yao et al., 2011). Aβ interacts with CypD, a 
mitochondrial matrix protein that associates with the inner membrane during the opening of the 
mitochondrial permeability transition pore (PTP) (Du et al., 2008). Cortical mitochondria from 
CypD-deficient mice are resistant to Aβ- and calcium-induced mitochondrial swelling and 
permeability transition. Moreover, Tg mAPP/CypD-null mice exhibit improved learning and 
memory and synaptic function both in 12- and 24-month-old animals (Du et al., 2008; Du et al., 
2011). Inside the mitochondria, presequence protease (PreP), could degrade Aβ (Falkevall et 
al., 2006). PreP can degrade Aβ40 and Aβ42, as well as Aβ Arctic protein (E22G) at unique 
cleavage sites, including several sites in the hydrophobic C-terminal Aβ segment that is prone 
to aggregate. Interestingly, PreP is an organellar functional analogue to the human insulin-
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degrading enzyme (IDE). The importance of PreP in AD was recently further emphasized in 
reports that its activity was decreased in AD brain (Falkevall et al., 2006). The presence of Aβ 
in mitochondria indicates that it is produced inside mitochondria or taken up from the outside, 
or both. Most likely, it is taken up from outside, despite finding that both APP 
(Anandatheerthavarada et al., 2003) and γ-secretase complexes (Hansson et al., 2004) are 
detected in the mitochondria (Pavlov et al., 2011). Our laboratory has shown that Aβ is 
imported via the common mitochondrial import pore and thereafter localized to mitochondrial 
cristae (Hansson Petersen et al., 2008). APP, on the other hand, accumulates in the import pore 
of AD brain mitochondria, after the import having been arrested due to the acidic sequence 
described above (see the subheading “Amyloid precursor protein”). A consequence of TOM 
blockage is dysfunctional import of nuclear encoded proteins important for respiratory chain 
activity (Devi et al., 2006). Therefore, both Aβ and APP in the mitochondria cause 
mitochondrial abnormalities, which could result in synapse loss, which are the most robust 
correlates of AD-associated cognitive deficits (Terry, 2000; Selkoe, 2002). Interestingly, Roses 
and colleagues recently found that a polymorphic poly-T variant in the TOMM40 gene could be 
used to estimate age-of-onset for late-onset AD (LOAD) in ApoE ε3 carriers (Roses et al., 
2009). ApoE ε3/4 carriers with long poly-T repeats linked to ApoE ε3 had an age of onset 7 
years earlier than individuals with shorter repeats. Whether the long poly-T repeat resulted in a 
modified TOM40 protein was unknown and needed investigation. In Paper II, we investigated 
this in fibroblast cells from ApoE ε3/4 carriers. However, we could not identify any deficits in 
mitochondrial functioning or morphology. This will be further discussed in the “Results and 
Discussion” section. 
 
1.5 MITOCHONDRIA-ASSOCIATED ER MEMBRANE (MAM) 
 
1.5.1 Distribution of mitochondria and ER in neurons 
In highly polarized cells such as neurons, bidirectional transport of various cargoes is of great 
importance. The dynamics have been observed for a variety of different organelles and vesicles 
including mitochondria, endosomes, proteosomes, lysosomes, peroxisomes, lipid droplets, 
secretory vesicles, viruses and intermediate filaments (Collins et al., 2002; Welte, 2004),). In a 
neuron, mitochondria are transported and accumulate where the need for ATP production is 
especially high. Mitochondrial distribution efficiency is essential for neuronal development and 
survival. To maintain local energy and meet metabolic demand in all cellular regions, 
bidirectional motion along the microtubules is governed by growth factor signaling (e.g. NGF) 
and phosphatidyl-inositol (Chada and Hollenbeck, 2003; De Vos et al., 2003). The neuronal 
mitochondrial pool is heterogeneous and different properties of isolated synaptic and non-
synaptic cortical mitochondria have been described, for example are the synaptic mitochondria 
more susceptible to calcium overload (Brown et al., 2006). Also the ER moves along the 
microtubules as both continuous networks and vesicular compartments (Waterman-Storer and 
Salmon, 1998; Bannai et al., 2004). The ER is a multifunctional organelle involved in protein 
folding and assembly, disulfide bond formation and calcium storage and to fulfill its many 
functions, the ER consists of specialized sub regions (Sitia and Meldolesi, 1992). At distal 
regions of the neurons, in for example spines, ER and mitochondria regulate calcium transients 
and, thereby, synaptic transmission (Pivovarova et al., 2002). Correct calcium handling by the 
two organelles and the calcium signaling between them is controlled by microtubules (Mironov 
et al., 2005). The interaction between ER and mitochondria in the synapse has been postulated 
to shape intracellular calcium signals and modulate synaptic and integrative neuronal activities 
(Mironov and Symonchuk, 2006). The specialized region of ER responsible for this interaction 
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is called the mitochondria-associated ER membrane (MAM) (Rizzuto et al., 1998; Csordas et 
al., 2006; Hayashi et al., 2009). Extensive investigation of the ER-mitochondrial interplay has 
been performed in yeast; however, limited research has been conducted on this interaction in 
cells of the brain. This will further be discussed in the next paragraph. 
 
1.5.2 MAM the control station  
Mitochondria and ER, important modulators of several pathways, are connected at specific 
contact points at a highly specialized region of ER called the mitochondria-associated ER 
membrane (MAM). At these points the metabolism of glucose, phospholipids, fatty acids, and 
cholesterol, as well as calcium homeostasis and apoptosis is regulated (Hayashi et al., 2009), 
(Simmen et al., 2005). Defective processes here could account for abnormalities routinely 
detected in AD patients, including: elevated cholesterol (Stefani and Liguri, 2009), altered fatty 
acid (Martin et al.), glucose (Hoyer et al., 1988), phospholipid (Pettegrew et al., 2001) 
metabolism, and abnormal calcium homeostasis (Bezprozvanny and Mattson, 2008). To date, 
more than two dozen proteins have been found to be concentrated in MAM (Area-Gomez et al., 
2009) including proteins involved in calcium homeostasis (e.g. inositol triphosphate receptor 
isoform 3 [IP3R3] and Sigma non-opioid intracellular receptor 1 [Sigma1R]), in lipid 
metabolism (e.g. fatty acid co-A ligase 4 [FACL4] and phosphatidylserin synthase 1 [PSS1]), in 
intermediate metabolism (e.g. glucose-6-phosphatase), in cholesterol metabolism (e.g. acyl-
coenzyme A: cholesterol acyltransferase 1 [ACAT]), and in apoptosis regulation (phosphofurin 
acidic cluster sorting protein 2 [PACS2]) (Rusinol et al., 1994; Hayashi et al., 2009) (see Figure 
6). Increased ER-mitochondrial coupling has been shown to promote mitochondrial respiration 
and bioenergetics during early phases of ER stress (Bravo et al., 2011). 
 
 
 
Figure 6. Illustration of signal transduction and metabolism at the MAM region. PACS2 can translocate 
tBid to the mitochondria and thereby induce cell death. Calcium is transported from ER to mitochondria 
via IP3R3-grp75-VDAC1 complex. Sigma1R (Sig1R) that normally is bound to BiP regulates the IP3R3 
channel. Inside the mitochondria calcium activates enzymes in the TCA cycle leading to enhanced ATP 
production. Calcium can be transported back to MAM and at MAM be bound to chaperones, e.g. 
calnexin (CNX), calreticulin (CRT) and Bip. The phospholipid, phosphatidylserine, produced by PSS1 in 
MAM is transported over to the mitochondria to be converted to phosphatidylethanolamine (PtdEtn), 
which either is used for cardiolipin synthesis or transported back to MAM for conversion into 
phosphatidylcholine. Cholesterol is produced in ER and for the synthesis of steroids and neurosteroids, 
cholesterol is transported to the mitochondria for the conversion to pregnenolone (Preg), which then is 
transported back for the synthesis of progesterone (Prog). Since the γ-secretase complex has been 
postulated to exhibit high activity at MAM we speculate that at these tight ER-mitochondria contact 
points, Aβ is transported over and into the mitochondria. 
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1.5.3 MAM is connected to the mitochondria by tethering complex/es 
The MAM region has been extensively studied in yeast. In this organism MAM is, apart from 
the above-mentioned processes, also involved in coordinating mitochondrial DNA replication, 
growth, protein import and maintenance of proper tubular morphology of mitochondria 
(Kornmann et al., 2009). Moreover, the tethering complex that couples ER to mitochondria has 
been described and is composed four proteins (Mmm1, Mdm12, Mdm10 and Mdm34). This 
complex is called the ER-mitochondria encounter structure (ERMES) (Kornmann et al., 2009). 
Disruption of ERMES impairs phospholipid exchange between ER and mitochondria since the 
enzymes responsible are located at either the MAM or the mitochondrial side. Recently, another 
study performed in yeast showed that proteins involved in shaping ER (called lastins in 
mammals) also play a role in maintaining functional contacts (Voss et al., 2012). Little is 
known about MAM in mammals and no homologues for ERMES components have yet been 
found. Several proteins have been suggested to participate in ER-mitochondrial bridging 
including IP3R, VDAC, grp75, Sigma1R, PACS2 and Mfn2 (Hayashi et al., 2009). 
 
1.5.4 MAM regulates apoptosis 
The ER-mitochondrial interface regulates apoptosis by several pathways, including calcium 
control and Bid translocation by PACS2 (Grimm, 2012). PACS2 is a multifunctional sorting 
protein that controls ER-mitochondrial communication, membrane traffic and apoptosis 
(Youker et al., 2009). PACS2 KO by RNAi causes loss of MAM-mitochondrial coupling and 
mitochondrial fragmentation (Simmen et al., 2005). In response to apoptotic stimuli, PACS2 
binds dephophorylated Bid and traffics Bid to mitochondria where Bid is cleaved into its active 
form, truncated Bid (tBid) (Simmen et al., 2005). At the mitochondria, tBid interacts with Bax, 
promoting its insertion and oligomerization causing membrane permeabilization and the release 
of apoptotic molecules (see Figure 1 and Figure 6).  
 
1.5.5 MAM controls calcium homeostasis 
Calcium is a highly versatile second messenger that controls critical cellular responses, and 
which requires tight regulation, especially at the synapse where spatio-temporal patterning of 
calcium signaling is important for proper transmission. Calcium is essential for the enzymatic 
activity of many metabolic pathways in the mitochondria. However, excessive amounts can 
cause calcium overload accompanied by opening of the PTP pore enabling release of apoptotic 
mediators. Many proteins at MAM control the shuttle of calcium, thereby regulating the 
metabolic state of the mitochondria. The ATP produced provides energy for the SERCA pump 
to reload ER with calcium. Calcium is transported into the mitochondria via IP3R3 located at 
the ER side and the voltage-dependent anion channel (VDAC1) in the OMM (see Figure 6). 
This calcium signaling regulates mitochondrial metabolic activity since several enzymes in the 
TCA, require calcium to be active. One protein thought to regulate calcium transport is 
Sigma1R, which normally binds to the calcium binding chaperone, BiP; and, upon activation 
after ligand binding or by decreased luminal calcium concentration, BiP and Sigma1R, 
dissociates and Sigma1R becomes active. The upregulation and redistribution of Sigma1R after 
ER stress mediates cell protection against apoptosis. Sigma1R has been shown to interact with 
various ion channels and Ankyrin B (Hayashi and Su, 2001; Maurice and Su, 2009). Recently, 
Sigma1R has been shown to regulate ER-to-mitochondria calcium fluxes by stabilizing the 
IP3R3 channel by preventing degradation by the ubiquitin-proteosome system (Hayashi and Su, 
2007).  IP3R3 is also regulated by anti-apoptotic factors (e.g. Bcl-2), the interaction by which is 
thought to prevent mitochondrial calcium overload (Hayashi and Su, 2007).  
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1.5.6 The role of Sigma1R at MAM 
Sigma1R has, apart from being involved in calcium signaling, been described as a unique 
ligand-regulated molecular chaperone, involved in the activity of several neurotransmitter 
systems (especially cholinergic and glutamatergic pathways), cell survival (Bcl-2 expression), 
learning processes, memory, mood alteration and regulation of hippocampal dendritic spine 
formation (Hayashi and Su, 2007; Tsai et al., 2009; Meunier and Hayashi, 2010; van Waarde et 
al., 2011). It is strongly expressed in both neurons and glia (Hayashi and Su, 2005). The 
intracellular localization of Sigma1R is mainly in lipid rafts in ER (i.e. MAM) but also nuclear, 
plasma membrane and mitochondrial localization has been described (Klouz et al., 2002; van 
Waarde et al., 2011). Sigma1R was first mischaracterized as an opioid receptor but later 
identified as a unique ligand-regulated molecular chaperone acting primarily at the MAM (Su et 
al., 1988; Hayashi and Su, 2003; Hayashi and Su, 2007). It has high affinity for diverse classes 
of psychotropic drugs (e.g. psychotomimetic drugs and neuroleptics), and has been proposed to 
play a role in a variety of diseases, including addiction, amnesia, pain, depression and stroke 
(Maurice and Su, 2009). To date, no endogenous ligands have been verified, however, 
neurosteroids, the hallucinogen, N,N-Dimethyltryptamine (DMT), and shingolipids have been 
suggested as agonists, and progesterone suggested as an antagonist (Fontanilla et al., 2009; 
Ramachandran et al., 2009; Johannessen et al., 2011). Activation of Sigma1R has been 
associated with anti-amnesic and neuroprotective effects and has been shown to protect against 
various pathological conditions including delirium in AD patients, ischemia, diabetes, 
inflammation, as well as Aβ toxicity (Marrazzo et al., 2005; Meunier et al., 2006; Furuse and 
Hashimoto, 2010; Ruscher et al., 2011). This will be discussed more in detail under the 
subheading “Treatment strategies”.  
 
1.5.7 MAM regulates lipid synthesis 
Enzymes in phospholipid and cholesterol synthesis pathways are localized on the MAM side 
and the mitochondrial side, calling for close contact between MAM and mitochondria for 
proper synthesis. Phospholipid biosynthesis is carried out as follows; phospatidylserine 
synthase (PSS1) is located at MAM and catalyzes the formation of phophatidylserine (PtdSer) 
from serine, which is transported into the mitochondria where it is converted to 
phosphatidylethanolamine (PtdEth) by phosphatidylserine decarboxylase. This intermediate is 
either used in the mitochondria to form cardiolipin or transported back to MAM for the 
conversion into phosphatidylcholine (major component of biological membranes) by the 
phosphatidylethanolamine methyltransferase-2 located in MAM (Hayashi et al., 2009) (see 
Figure 6). A reduced rate of lipid exchange, in turn, slows down aminoglycerophospholipid 
turnover, resulting in impaired cardiolipin synthesis accompanied by decreased mitochondrial 
membrane maintenance. Synthesis of steroids also depends on shuttling between ER and 
mitochondria since cholesterol, after its synthesis in ER, is transported to mitochondria for the 
catalyzed reaction by the cholesterol side-chain cleavage enzyme, forming pregnenolone, which 
then is transported back to ER for the synthesis of progesterone and several other steroids and 
neurosteroids (e.g. allopregnenolone, dehydroepiandrosterone) (Baulieu et al., 2001). Mounting 
evidence also indicates that localized in MAM are enzymes involved in ceramide and 
sphingolipid metabolism (Rusinol et al., 1994; Bionda et al., 2004). 
 
In AD, a reduction in phospatidylethanolamine (Pettegrew et al., 2001) and alterations in 
cholesterol metabolism have been detected (Stefani and Liguri, 2009)). The deranged 
biosynthesis of cholesterol in ER is thought caused by e.g. Seladin-1 downregulation. This in 
turn lowers the level of cholesterol in lipid rafts, which has been associated with increased Aβ 
production signifying the importance of functional cholesterol biosynthesis (Bionda et al., 
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2004). This is further supported by the finding that the neurosteroid, allopregnenolone, is 
reduced in the prefrontal cortex of AD patients (Marx et al., 2006). Interestingly, treatment with 
allopregnanolone reverses cognitive deficits in a triple transgenic mouse model of AD (Marx et 
al., 2006). Moreover, variations in plasma levels of sphingomyelins and ceramides are early 
predictor of memory impairment (Mielke et al., 2010). Thus, abnormal lipid metabolism in the 
brain could impair membrane lipid homeostasis, membrane repair and steroid signaling, and 
ultimately result in deteriorating synapses and neuronal networks. 
 
1.5.8 Can Aβ be transported into the mitochondria from MAM? 
Interestingly, both APP and the γ-secretase complex are enriched in MAM in mouse brain. 
Furthermore, γ-secretase has been demonstrated to exert its highest activity at MAM (Area-
Gomez et al., 2009). This suggests that Aβ might be produced in MAM where the close 
proximity to the mitochondria might enable Aβ translocation into the mitochondria, and 
consequenly cause damage (see Figure 6). Thus, we believe that MAM harbors important clues 
for understanding AD-pathophysiology.  
 
 
1.6 TREATMENT STRATEGIES 
To date, as described above, there are two classes of drugs approved to treat AD, cholinesterase 
inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonist (memantine). 
These drugs provide symptomatic relief but are weak agents modifying the disease 
pathophysiological process. Lately much effort has been made to find disease-modifying drugs 
that are targeted to reduce Aβ production (γ-secretase inhibitors/modulators, BACE1 
inhibitors), prevent its aggregation or promote its clearance (active/passive immunization); or to 
affect tau phosphorylation and assembly. Unfortunately, none of these drugs have demonstrated 
efficacy in Phase III clinical trials. The failures of these clinical trials have raised a number of 
questions, from who to include in a clinical trial, to questions about our understanding of AD 
pathophysiology and biology. Hence, AD is increasingly considered as a heterogeneous and 
multifactorial disease that needs to be treated early with drugs covering multiple targets, the 
mitochondrion being one of them (Ankarcrona et al., 2010; Mielke et al., 2010). We believe 
that therapeutic interventions that affect the MAM region or the mitochondria could restore 
healthy regulation of glucose and lipid metabolism, calcium homeostasis and cell death 
signaling, each of which is evidently disturbed in AD.  
 
1.6.1 Targeting MAM dysfunction 
 
1.6.1.1 Targeting lipid metabolism 
The lipid metabolism, as described earlier, is dysfunctional in AD. This could be due to altered 
regulation or ineffective transport of lipid intermediates between ER and mitochondria. 
Membrane cholesterol in lipid raft has been suggested to play a role in Aβ formation (Crameri 
et al., 2006). Lowered expression of seladin-1, an enzyme involved in cholesterol synthesis in 
ER, has been detected in AD, and studies in animal models demonstrate that lowering of 
cholesterol in lipid rafts increases Aβ generation, substantiating the importance of functional 
cholesterol biosynthesis (Crameri et al., 2006; Stefani and Liguri, 2009). This is further 
supported by the fact that inhibitors against ACAT, the enzyme converting membrane 
cholesterol into cytoplasmic cholesterol-ester have been shown to reduce amyloid pathology in 
an AD mouse model (Puglielli et al., 2001; Hutter-Paier et al., 2004). In addition, treatment 
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with the neurosteroid, allopregnanolone, has shown promising results in a triple transgenic 
mouse model of AD (Wang et al., 2010). 
 
1.6.1.2 Targeting Sigma1R 
Sigma1R is another promising target at MAM and is implicated in cellular differentiation, 
neuroplasticity, neuroprotection and cognitive processes of the brain (Marrazzo et al., 2005; 
Hayashi and Su, 2008). Several drugs show affinity for Sigma-1R, including donepezil, 
antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, 
sertraline) and monoamine oxidase inhibitors (clorgyline) (van Waarde et al., 2011). Depletion 
of Sigma1R by RNA interference (RNAi) causes inhibition of growth, survival-signaling 
cascades and induces cell death. The antagonist, rimcazole, produces the same effect. Sigma1R-
KO mice display depressive, anxiety-like phenotype and altered motor behaviors. Moreover, 
the female mice demonstrated reduced levels of 17β estradiol levels and memory deficits 
associated with age (van Waarde et al., 2011). Treatment of aged rats with Sigma1R agonist 
(PRE-084) improved the spatial learning deficits that had emerged with age (Maurice, 2001). 
Furthermore, Sigma1R activation (by the agonist SA4503) stimulates recovery after stroke by 
enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain 
plasticity (Ruscher et al., 2011). Polymorphisms in the sigma1R gene have been linked to 
frontotemporal lobe dementia (Luty et al., 2010). A positron emission tomography (PET) study 
of AD patients concluded that the density of Sigma1R is lower early in AD pathogenesis. 
(Mishina et al., 2008). Similarly, reduced number of Sigma1R-binding sites is found in the CA1 
area of the hippocampus in AD, which correlates with pyramidal cell loss in this region (Jansen 
et al., 1993). The mechanism of action of Sigma1R agonist is not fully understood, however, it 
is possible that it involves ER-to-mitochondria calcium fluxes via stabilization of IP3R3, 
thereby activating the calcium sensitive enzymes in the TCA cycle. Increased formation of ATP 
can, in turn, stimulate neuroprotection and neurite outgrowth leading to improvements in 
cognition and cerebral metabolism (Hayashi and Su, 2007). As we reported in Paper III, 
Sigma1R is also present in mitochondria, though its function is mostly unknown. However, our 
data suggest that it can modulate calcium uniporters in the IMM. Indeed, regarding the mode of 
action, much information points toward a role in regulation of calcium channels and since 
calcium homeostasis is altered in AD, Sigma1R agonist treatment potentially might aid its 
restoration. Taking into account the neuromodulatory role of the Sigma1 receptor, agonists can 
affect a large variety of processes in neurons, and in glia cells (astrocytes and 
oligodendrocytes), and, thereby, perform neuroprotective actions. Sigma1R agonists might, 
therefore, be of interest as an AD-therapeutic agent especially targeted to early disease stages 
where it can increase cellular resistance against various pathogenic processes.  
 
1.6.1.3 Targeting cell death processes 
MAM encompasses crucial determinants of life and death, including calcium signaling, Bcl2 
family members and PACS2 (Decuypere et al., 2011). Rupture of the OMM plays a crucial role 
in the intrinsic cell death pathway and causes caspase activation. Drugs that interfere with 
caspase activation might provide therapeutic effect by, for instance, hindering caspase cleavage 
of IP3R3 (causes mitochondrial calcium overload) (Decuypere et al., 2011), PS1 (causes 
elevation of Aβ42/Aβ40 ratio, see Paper I) and tau (required for tau hyperphosphorylation) (de 
Calignon et al., 2010). The drug doxycycline averts Aβ toxicity by preventing Aβ fibrillization 
by inhibiting caspase 3 activation, as shown in studies using a neuroblastoma cell line and in a 
Drosophila AD model (Costa et al., 2011). However, many peptides designed to directly 
inactivate caspases, e.g. z-VAD or z-LEHD-FMK, have shown successful therapeutic effect 
against neuronal injury after hypoxia and cerebral ischemia injuries in vivo, yet have been 
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found to be ineffective for neuroprotection. Caspase inhibitors disturb the normal homeostasis 
of the cell and might cause activation of alternative pathways of death. Therefore, caspase 
inhibition might not be effective as AD treatment. Alternatively, drugs targeting mitochondrial 
function may be more promising since these could prevent the release of pro-apoptotic factors. 
 
1.6.2 Targeting oxidative stress 
Strategies targeting oxidative and nitrosative stress, which are considered important players in 
AD onset and progression, hold disease-modifying potential (Ankarcrona et al., 2010). Several 
interventions make it possible to overcome challenges of ineffective uptake over the BBB and 
limited concentration in the mitochondria (Murphy and Smith, 2007). One strategy is to 
conjugate the antioxidant to lipophilic cations for example using triphenylphosphonium (TPP+), 
which enable rapid BBB and neuronal membrane crossing and to be concentrated (several 
hundred-fold) in the mitochondria (Murphy and Smith, 2007). Applying this technique, MitoQ 
and Mito-E2 were developed. MitoQ is a compound that brings reducing power into the 
mitochondria in form of coenzyme Q10 (ubiquinone), an endogenous antioxidant and 
component of the mitochondrial electron transport chain, and which show potential in AD 
animal models (McManus et al., 2011). Mito-E2 brings vitamin E into the mitochondria, and 
has also shown promising results in cell and animal models (Murphy and Smith, 2007; Leo et 
al., 2008). Moreover, the drug methylene blue (MTC), a tau antiaggregant, has shown 
promising results in clinical trials (Gura, 2008). Apart from affecting tau aggregation, MTC 
also has other properties, including function as an antioxidant (Atamna et al., 2008), as an 
alternative electron carrier that bypasses complex I/III (Wen et al., 2011) and can induce 
autophagy (Congdon et al., 2012). Interfering with mitochondrial ROS overproduction with 
mitochondrial-targeted catalase lengthen life span in mice (Schriner et al., 2005) and reduces 
abnormal APP processing in a AD mouse models (Schriner et al., 2005). Some antioxidants, 
e.g. trolox or superoxide dismutase, have also been shown to reduce Aβ production by 
reversing elevation of BACE1 activity apparent after ischemia (Guglielmotto et al., 2009). In 
the mitochondria, Aβ can interact with ABAD as described earlier. Small molecules that 
interfere with this interaction have emerged as additional potential drug targets for AD (Xie et 
al., 2006).  
 
1.6.3 Dimebon 
Mitochondrial dysfunction is evident in AD already at early stages in the disease progression. 
Therefore, rescuing mitochondrial functions is a promising therapeutic strategy since it could 
have disease modifying effect. The drug, Dimebon (Latrepirdine), which showed pro-cognitive 
and neuroprotective effects in a Russian Phase II clinical trial (Doody et al., 2008), was a new, 
hot candidate for AD treatment. Dimebon was originally approved as an antihistamine in the 
former Soviet Union in the 1980’s (Matveeva, 1983) but was withdrawn from the market with 
the advent of more effective treatments. However, research on Dimebon continued. Around 
year 2000, it received renewed interest due to discovery of its neuroprotective effects 
(Lermontova et al., 2000; Bachurin et al., 2001; Wu et al., 2008). Dimebon’s mode of action 
was unknown. It showed low affinity to acetylcholinesterase and NMDA receptors, yet high 
affinity to histamine, adrenergic, dopaminergic and serotonergic receptors. In our laboratory, 
we explored its mode of action and concluded that some of its neuroprotective effects could be 
mediated via stabilizing mitochondrial function (as shown in Paper IV). This will be further 
discussed in the section “Results and Discussion”. Unfortunately, recently, two Phase III AD 
clinical trials failed to meet primary and secondary efficacy endpoints. The CONNECTION 
study was designed akin to the Russian phase II clinical trial. In this trial that was conducted for 
one year, mild-to-moderate AD patients were enrolled and received either Dimebon or placebo 
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for six months. Thereafter, the trial was designed so that also the placebo group where given 
Dimebon. The results after six-month treatment showed no significantly change from baseline, 
in either group. The CONCERT study was designed as a double drug-therapy trial, in which 
Dimebon was an add-on to donecepil. Also in this study, mild-to-moderate AD patients were 
enrolled. This study was conducted for one year, after which, again, the study failed to meet the 
endpoint criteria. Thus, Dimebon failed to show improvement of cognition in AD at mild-to-
moderate disease stage. Perhaps, treatment provided at an earlier disease stage, prior to the 
widespread pathology and neuronal loss as would be later manifest could bring greater efficacy. 
Dimebon will be further discussed in the section “Results and Discussion”. 
 
In summary, targeting MAM and/or mitochondria could potentially reverse failing 
mitochondrial bioenergetics, including glucose and lipid metabolism, calcium homeostasis, 
ROS production, intracellular Aβ production and cell survival. Therefore, these targets 
represent promising strategy for AD therapy.  
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2 AIMS 
The general aim of this thesis was to explore mechanisms underlying mitochondrial 
dysfunction in AD bringing into focus regulatory mechanisms and caspase activation. 
Mitochondria are key players in determining cellular fate, including life or death decisions. 
Already subtle changes in the intracellular Aβ42/Aβ40 ratio are linked to Aβ oligomerization 
and toxicity, which has been observed during mitochondrial ROS production and activation of 
caspases.  
• Paper I. To investigate by what mechanism caspases alter the intracellular 
Aβ42/Aβ40 ratio and to explore implications of these mechanisms for sporadic AD.  
Intracellular Aβ has been found to accumulate in the mitochondria where it causes damage to 
metabolic pathways, mtDNA repair and increases the likelihood of PTP opening. Aβ might be 
produced in MAM, subsequently transported over to the mitochondrial side, and imported via 
the TOM40 pore, the common import machinery through which all nuclear-encoded 
mitochondrial protein has to be transported. The TOMM40 gene is in linkage disequilibrium 
with the APOE gene and polymorphisms exist that are associated with AD. 
• Paper II. To study functional implications of the recently identified poly-T repeat in 
the TOMM40 gene linked to lowered age-of-onset of LOAD in ApoE ε3/4 carriers, in 
regards to mitochondrial function.  
MAM regulates vital biological processes, including metabolism of glucose and lipids, calcium 
homeostasis and regulation of cell death, all of which become dysregulated in AD. Both ER and 
mitochondria are important players in maintaining proper synaptic function. However, little is 
known about MAM in neurons, especially as concerns AD perspective. 
• Paper III. To examine the importance of MAM for neuronal survival, and in relation 
to AD pathogenesis. 
Treatment strategies targeting the mitochondria could have beneficial disease modulatory 
effects since increasing the mitochondrial resistance towards cellular stressors could strengthen 
the synapses and thereby hinder dysfunction and loss of synapses. 
• Paper IV. To investigate mode of action of Dimebon, a potential novel drug for 
treatment of AD. 
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 ETHICS APPROVAL 
Ethical permissions for using animal and human tissues were obtained from the Regional Ethics 
Committee for Animal Research in Stockholm South and the Regional Ethics Committee of 
Stockholm. 
 
3.2 MODELS USED IN THE STUDIES 
For conducting these studies we have used a variety of models systems including conventional 
cell lines, human fibroblast cell cultures derived from biopsies, mouse primary neuronal cell 
cultures, AD-mouse models (APPSwe/Lon and APPArc) and human postmortem cortical brain 
tissue. 
 
3.2.1 Cells 
The conventional cell lines used included mouse blastocyst (BD8) cells in Paper I and 
neuroblastoma (SH-SY5Y) cells in Papers I, III and IV. Conventional immortalized cell lines 
are an excellent tool used to study molecular and cellular processes in a simple and controlled 
environment and do not require ethical permission. However, they are usually poor 
representations of cells found in intact tissues. The SH-SY5Y cell line, which is a cancer cell 
line, can be differentiated into neuronal-like cells upon retinoic acid treatment that induce 
attenuation of proliferation and extension of neuritic processes (Paper IV). This model 
represents a good substitute to primary neuronal cultures since it does not require sacrificing 
animals. Nevertheless, for a more comprehensive analysis of processes occurring in neurons, 
primary cultures are needed. Here, we have used cortical (Paper IV) and hippocampal (Paper 
III) primary neurons from mouse embryos. In Paper II, we used fibroblast cell cultures 
generated from skin biopsies from individuals in AD families. 
 
3.2.2 Human postmortem tissue  
To study how expression of different proteins is affected in AD, we have used human 
postmortem cortical tissue (Paper III), which is of great value for studying disease 
mechanisms. However, cautions should be taken since postmortem tissue represents the end 
stage of the disease and does not give information about progressive mechanisms. Moreover, 
differences between sample handling and postmortem times can differ substantially and thereby 
affect protein expressions. 
 
3.2.3 Transgenic mouse models 
To be able to follow disease progression transgenic mouse models, APPSwe/Lon and the APPArc, 
have been used (Paper III). The APPSwe/Lon mouse model overexpresses the Swedish 
(K670N/M671L) and London (V717I) mutation and, subsequently, accumulates large 
quantities of dense-core and diffuse amyloid plaques (see Figure 7) (Rockenstein et al., 2001). 
The APPArc mouse model overexpresses the Arctic mutation (E693G), which is an intra-Aβ 
mutation (see Figure 7) that gives rise mainly to diffuse Aβ deposits (Ronnback et al., 2012). 
The APPArc model has a milder amyloid pathology affecting primarily the subiculum as 
opposed to the APPSwe/Lon mouse model that develops mature plaques as early as 3-4 months 
and exhibits widespread amyloid pathology, affecting neocortex, hippocampus, thalamus and 
olfactory regions. Studying these two animal models can give valuable information on how 
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different Aβ pathologies (Aβ-peptides vs. AβArc-peptides) affect particular biological processes 
and pathways at different stages of disease. Nevertheless, the pathology in animal models does 
only represent some aspects of AD; tau pathology, for instance, is lacking. Therefore, one 
should be cautious when interpreting data acquired from transgenic animals.  
 
 
 
Figure 7. Illustration of APP showing the cleavage sites for α-, β-, and γ-secretases and the position of Swedish, 
Arctic, London and Indiana mutations.    
 
3.3 QUANTITATIVE MEASUREMENTS OF PROTEIN EXPRESSION 
For quantification of protein levels, we used Western blot (Paper I, II and III) and enzyme-
linked immunosorbent assay (ELISA) (Paper I and III). Both these methods are based on 
antibody detection. Antibodies have affinity for specific epitopes that at certain circumstances 
can be hidden in the proteins. This can be caused by for example conformational changes and 
aggregation. Therefore, this is something that is important to keep in mind when interpreting 
data generated from antibody-based methods. 
A good complement is immunohistochemistry, which was used in Paper III, and with which 
protein expression levels can be visualized and studied in different brain regions. This method 
is, however, more qualitative than quantitative. Another method used for detection of proteins is 
liquid chromatography-mass spectrometry (LC-MS), which can be either qualitative or 
quantitative depending on internal standards. In Paper I, an ion-trap mass spectrometer 
(Agilent 6330) was used to qualitatively analyze Aβ-peptides secreted from cell lines with the 
aim of identifying long Aβ-peptides (>Aβ42). This was however, not fully successful; though 
Aβ42 could be detected and this information used to verify our earlier ELISA data. 
 
3.4 SUBCELLULAR FRACTIONATION 
Many proteins reside in certain compartments within the cells, and are destined for specific 
activities. Their intracellular localization can be studied by subcellular fractionation. In order to 
investigate protein expression at the MAM region and to study ER-mitochondrial contacts in 
synapses (in Paper III) we fractionated mouse brains on percoll gradients according to 
previously described protocols (Dunkley et al., 2008; Wieckowski et al., 2009). Caution should 
be taken when interpreting pureness of fractions after subcellular fractiontion since these almost 
certainly contain contamination from other cellular regions, generating artifacts. Therefore, for 
comprehensive analysis of pureness, expression of several organelle specific proteins could be 
studied by Western blot and the fractions could be studied by electron microscopy. 
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3.5 EXPOSING CELLS TO Aβ  
Studying the impact of Aβ on various biological processes is important to understand AD 
pathogenesis. However, which Aβ species (Aβ40, Aβ42) and assembly forms (monomer, 
oligomer, fibrils) are the most toxic is highly debated. Currently, soluble oligomers (beta-sheet 
structures) are thought to have more influence on toxicity than monomers (α-helical or random 
coil structures) or fibrils (parallel beta-sheet conformation) (Iversen et al., 1995). We chose, in 
Paper III, to use conditioned media from the well characterized CHO7PA2 cell line that 
overexpresses the Indiana mutation (APPV17F) (see Figure 7), primarily secreting oligomeric 
Aβ species (Walsh et al., 2002). Our selected concentration for Aβ in our experiments were 
either 2.5 nM or 4.5 nM (total Aβ40 and Aβ42), which are thought to resembles concentrations 
that neurons are exposed to in the brain (Cleary et al., 2005).  
 
3.6 STUDY MITOCHONDRIAL FUNCTION 
There are several ways to study mitochondrial function. Here, we used techniques that assess 
different aspects including ΔΨm (Paper II, IV), complex II activity by MTT-assay (Paper IV), 
ATP production (Paper IV) and mitochondrial biogenesis (Paper II and IV). MTT assay is a 
colorimetric technique, in which the color change that occurs when tetrazolium salt is reduced 
to formazan is measured. This reaction is mainly catalyzed by complex II in the electron 
transport chain and is, therefore, an indicator of the cells redox activity. Maybe however, other 
enzymes residing in the cytosol also have this capacity and, therefore, cautions ought to be 
made when interpreting activity as strictly mitochondrial oriented. ATP levels are studied, as a 
measure of the coupling of OXPHOS, here, by employing a luminescent method (Paper IV). 
However, a more illuminating view of the bioenergetic state of the mitochondria could be given 
assessing the ADP/ATP ratio. The ΔΨm is used to drive the phosphorylation of ADP at 
complex V in order to generate ATP. To monitor alternations in the ΔΨm, the cationic dye 
TMRM, which accumulates inside the mitochondria in proportion to the ΔΨm, was used. 
Mitochondrial biogenesis was assessed by one of two different ways, either by quantifying 
mitochondrial volume density on electron microscopy pictures (Paper II) or by quantifying 
mtDNA copy number by quantitative real time PCR (Paper IV). The measurement using 
electron microscopy pictures was performed by point counting using a 2 cm and 1 cm square 
lattice (Weibel 1979).   
 
3.7 VISUALIZATION OF PROTEINS AND ORGANELLES IN FIXED 
SAMPLES 
Confocal microscopy is a widely used tool to study various cellular processes since it enables 
visualization along one focal plane by employing a spatial pinhole that eliminates out-of-focus 
light, increasing optical resolution and contrast. Since only one focal plane is visualized, it 
enables visualization of protein and organelle interactions. Using the Zeiss LSM510 META 
confocal microscope we imaged chromatin condensation (Paper I), distribution of MAM 
proteins (Paper III), and ER- mitochondrial interactions (co-localization) after Aβ treatment 
(Paper III). For this purpose we used 2D co-localization method in the LSM 510 software 
program. However, care must be taken when attributing significance to the 2D method since 
signals used in calculations might originate from outside the focal plane of interest. Therefore, 
3D methods have gained increased interests since the calculated co-localization originates from 
volume reconstruction and, therefore, has the capacity to reduce these problems. 
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Transmission electron tomography (TEM) is a method to image cellular structures with higher 
magnification. This technique utilizes a beam of electrons to increase the resolution instead of 
photons, which are used in a regular microscope to create the image. We used this technique to 
study mitochondrial morphology (Paper II) and ER-mitochondrial interactions in 
synaptosomes (Paper III).  
 
3.8 LIVE CELL IMAGING 
Live cell imaging is a widely used technique to study dynamic networks in cells. We performed 
several live cell analyses using the Zeiss LSM510 META confocal microscope, including 
visualizing of ΔΨm using the dye TMRM (Paper II, IV), viability of hippocampal neurons 
after siRNA transfection (Paper III), and distribution of mitochondria and ER using Cell-Light 
probes (Paper III). For quantification of changes in ΔΨm, the TMRM intensities were 
analyzed at different time point using the LSM 510 software program. For this purpose it is 
important to ensure constant focus, which can be controlled by simultaneous visualization of 
e.g. nucleus. 
 
3.9 MEASUREMENT OF CALCIUM SIGNALING BETWEEN ER AND 
MITOCHONDRIA 
Spatiotemporal calcium measurements in intracellular compartments including ER, cytosol and 
mitochondria give valuable insights into biological processes. One method developed for this 
purpose utilizes aequorin, a protein isolated from a luminescent jellyfish. This protein is an 
apoenzyme and needs a prosthetic group (cofactor) for its function. The cofactor is 
coelenterazine, which contains several calcium binding sites. Upon calcium binding the protein 
undergoes a conformational change and through oxidation converts coelenterazine into the 
excited coelenteramide, which emits blue light when relaxing to its ground state. This emitted 
light can be measured by a luminometer. Advantages of using aequorin include easy 
transfection, that no optical excitation is needed and well tolerability by the cells. One limitation 
is, however, that the prosthetic group, coelenterazine, requires continuous addition since it is 
consumed when reacting with calcium. In Paper III we used this method to study the calcium 
signaling between ER and mitochondria. 
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4 RESULTS AND DISCUSSION 
 
4.1 MITOCHONDRIAL REGULATION AND DYSFUNCTION IN AD 
Low glucose metabolism and mitochondrial impairment are observed already at early stages of 
AD. The triggering events causing altered bioenergetics and mitochondrial dysfunction are not 
fully understood. We speculate that alterations in MAM functioning may partly underlie these 
defects. Glucose and lipid metabolism, calcium homeostasis and cell death regulation are 
processes that are impaired in AD, and all are controlled in MAM. Growing evidence also 
suggests that Aβ can be produced in MAM. For an illustrational overview of the Paper I to IV 
see Figure 8. 
 
4.2 CASPASE CLEAVAGE OF PS1 INCREASES THE Aβ42/Aβ40 RATIO  
The pathology of AD affects the regulation of cell death as demonstrated by aberrant activation 
of caspases, which is a prominent feature of AD and has been implicated in synaptic 
degeneration and neuronal loss (Stadelmann et al., 1999a; Louneva et al., 2008b; Albrecht, S. et 
al., 2009). Active caspases have been detected in cerebrospinal fluid and postmortem brain 
tissue of sporadic and FAD patients, and in AD-mouse models, and these correlate with 
elevated Aβ production (Tesco et al., 2003; Albrecht, P. et al., 2009). The mechanism by which 
caspase activation causes elevated Aβ is not fully understood. Caspases can cleave proteins 
involved in Aβ generation, including APP, PS1 and PS2; however, the truncation of APP does 
not seem to influence Aβ production (Tesco et al., 2003). The γ-secretase complex contains 
either PS1 or PS2. Those incorporating PS1 are more common and also more likely to be 
involved in APP processing (Franberg et al., 2011). Moreover, the majority of FAD mutations 
are located in PS1 as compared to PS2 or APP. PS1 can be cleaved at Asp333 and Asp345 in 
the loop region by several caspases including 1, 3, 6, 7, 8 and 11 causing the loss of half of the 
loop (Kim et al., 1997; van de Craen et al., 1999) (see Figure 3). The loop region has previously 
been shown to possess regulatory functions in regards to Aβ production (Deng et al., 2006). 
Therefore, in Paper I, we aimed to investigate caspase cleavage of PS1 more carefully. 
Previously, in our laboratory we had shown that PS1, despite the loss of half the loop domain 
after caspase cleavage (caspCTF), is still part of active γ-secretase complexes (Hansson et al., 
2006). Thus, we wanted to investigate if this truncation could change the cleavage preferences 
in APP. To do so, we established stable cell lines either expressing wild type CTF (wtCTF) or 
caspCTF. As expected, caspCTF formed active γ-secretase complexes together with Nicastrin, 
Pen-2, Aph-1 and PS1-NTF. When studying the Aβ profile generated from these γ-secretase 
complexes we identified a shift at the γ-site. The caspCTF-containing γ-secretase complexes 
had an increased intracellular Aβ42 production, resulting in a significant elevation of 
Aβ42/Aβ40 ratio as compared to wtCTF-containing γ-secretase complexes. Thus, the increased 
production of Aβ42 during apoptosis can be at least partly explained by the formation of 
caspCTF-containing γ-secretase complexes (see Figure 8). Interestingly, activation of caspases 
is not only a consequence of the pathophysiology of AD but is actually continuously occurring 
in a transient fashion in normal brain physiology. This is seen, for example, in neurons in which 
activation of caspase enables synaptic reorganization and neurite retraction. Therefore, 
activation of caspases is important for neuronal plasticity (Li et al., 2010). Consequently, 
caspase cleavage of PS1 could occur both under normal plasticity and in pathological 
conditions, during which caspases are activated. When studying the intracellular localization of 
caspCTF in healthy mouse brain we identified this truncated form of PS1 in several 
compartments, however, most abundantly in lysosomes, plasma membrane and, interestingly, 
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also in MAM (Paper III) (see Figure 8). This means that, locally in MAM, the Aβ42/40 ratio 
could be elevated to influence MAM’s many regulatory functions, and at this site, Aβ could be 
transported over into the mitochondria where damage could trigger mitochondrial dysfunction 
(see Figure 8). 
 
4.3 TOMM40 POLYMORPHISMS, IMPLICATIONS FOR AD 
Aβ has been detected inside the mitochondria in AD patients, and at an early stage of pathology 
in AD mouse models. Accumulation of Aβ inside the mitochondria has recently been shown to 
represent a phenomenon separating individuals with profound AD lesions into two groups one 
that develops AD and one that remains cognitively intact. The group that developed AD 
exhibited accumulation of Aβ in their mitochondria whereas the group that remained cognitive 
intact did not (Taglialatela, Poster, AAIC, 2012 Vancouver, Canada). Inside the mitochondria 
Aβ interacts with several proteins, e.g. complex IV, cyclophilin D and ABAD, which causes 
mitochondrial dysfunction. The pathway by which Aβ is transported into the mitochondria has 
previously been investigated in our laboratory showing that import follows the common rout 
via the Tom40-import pore, through which all the 1000 nuclear-encoded mitochondrial proteins 
are imported (Hansson Petersen et al., 2008) (see Figure 8). Several polymorphisms that have 
been associated with increased risk of late-onset AD have been identified in the TOMM40 gene. 
The TOMM40 gene is located on chromosome 19 in a region of linkage disequilibrium (LD) 
with APOE. Much effort is being brought to identify whether, in addition to APOE, the LD-
block contains other risk factors influencing AD. The polymorphism, rs10524523, in TOMM40, 
has received particular attention since one of its variants was shown to lower the age-of-onset of 
LOAD by 7 years in APOE ε3/4 carriers (Roses et al., 2009). Thymidine stretches of varying 
length in intron 6 comprise rs10524523. The linkage disequilibrium between the TOMM40 and 
APOE genes ensures that the ε4 allele will always be inherited along with a long poly-T repeat, 
whereas the ε3 allele is inherited with either a very long or a short poly-T repeat. In Paper II 
we used biochemical methods to investigate rs10524523. We could not detect any functional 
implications of this polymorphism in regards to (i) expression levels of TOM40 protein and 
mRNA, (ii) TOM40 mRNA splicing, or (iii) mitochondrial function and morphology. 
Therefore, we think that this specific polymorphism does not participate in a significant manner 
in mitochondrial dysfunction. However, several other polymorphisms might be worth 
investigating (see Figure 8). 
 
4.4 MAM IS MODULATED BY AD PATHOGENESIS 
MAM are connected to mitochondria and interaction between ER and mitochondria via its 
contact points are crucial for proper cell function. In AD, the disturbed glucose, phospholipid 
and cholesterol metabolism, the altered calcium homeostasis and the dysregulated cell death 
might indeed be linked to MAM alterations. Having found in the literature a scarcity of 
knowledge about MAM in the brain and in diseases like AD, we, in Paper III, set out to 
investigate it. We report, that (i) proteins enriched in MAM (e.g. PACS2, PSS1, Sigma-1R, 
IP3R3) are ubiquitously expressed in neurons and expressed both in soma and at distal parts of 
the neurites and in synapses, (ii) MAM function is essential for neuronal and astrocytic survival 
since siRNA treatment against PACS2 and Sigma-1R causes degeneration, and that (iii) the 
MAM region is altered in the human AD brain, and before the appearance of plaques, at least in 
the APPSwe/Lon mouse model. In addition, Aβ exposure at nM concentration of hippocampal 
neurons increased (i) the expression of MAM proteins, (ii) the number of contact points 
between ER and mitochondria and (iii) the transfer of calcium from ER to mitochondria, 
modulating especially calcium uptake mechanisms on the mitochondrial side, as shown in SH-
SY5Y cells treated with a combination of Aβ and Sigma-1R agonist. Thus, physiological 
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concentrations of Aβ do modulate ER-mitochondria contact points and calcium shuttling, from 
the ER to the mitochondria, causing an increase in mitochondrial-calcium concentration, which 
in the long run may lead to Ca2+ overload and neuronal toxicity. Our data indicate that ER-
mitochondria contacts could be affected by Aβ during the progress of AD pathogenesis and that 
MAM modulation may be involved in altered neuronal activity in AD (see Figure 8). This is the 
first study describing the distribution of MAM in the brain, the subcellular localization of 
MAM in neurons and the influence of Aβ on MAM protein expression, regulation of contact 
points and calcium transfer into mitochondria. Moreover, emerging evidence suggests that Aβ 
actually could be produced in MAM since high activity of the γ-secretase complex has been 
reported in the MAM region. In concordance, our data further support this theory since we also 
detected APP, C99 and PS in MAM (Paper III). Moreover, preliminary data also indicate that 
BACE1 is located there (data not shown). Interestingly, we also detected caspCTF in MAM, 
which locally could change the Aβ42/Aβ40 ratio at these spots. We suggest a novel function of 
Aβ as a regulator of ER-mitochondria contacts, which may result in altered mitochondrial 
function both under physiological and pathological conditions, depending on dose and time (see 
Figure 8). Aβ might regulate (i) calcium uptake into the mitochondria (Paper III) and thereby 
regulate the energetics of mitochondria, (ii) production of both cholesterol and sphingomyelin 
(Grimm et al., 2005) and (iii) fluidity of the lipid-raft like lipid bilayer that MAM is composed 
of, and do so by binding to sphingolipids. On the other hand, Aβ can (i) accumulate in the 
mitochondria causing severe damage, (ii) cause elevation of mitochondrial ROS production (iii) 
cause release apoptotic mediators from the mitochondria.  
 
 
 
 
 
Figure 8. Overview of the studies. In Paper I we showed that γ-secretase complexes containing caspCTF 
increase the intracellular Aβ42/Aβ40 ratio. In Paper II we studied a specific polymorphism in the 
TOMM40 gene consisting of a poly-T stretch with varying length. Even though no functional implication 
was found regarding this polymorphism, others could be worth investigating. In Paper III we found that 
the MAM region is altered in AD and the ER-mitochondria contact points and calcium transport increases 
after Aβ exposure. In the last study, Paper IV, we looked at the mode of action of a potential novel AD 
drug, Dimebon, and found that it enhances mitochondrial function and increases the resistance against 
various stressors. We hypothesize that Aβ produced at MAM could modulate the MAM region, modulate 
the amount/distance of ER-mitochondria contact points and be the region where Aβ is transported over to 
the mitochondria. 
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4.5 TARGETING MITOCHONDRIAL FUNCTION 
The final study, Paper IV, concerned the potential novel drug, Dimebon (Latrepiridine), 
intended for treatment of AD (Doody et al., 2008). We investigated Dimebon’s mode of action 
in two in vitro models, primary mouse cortical neurons and SH-SY5Y cells. After one to five 
days incubation with nM concentrations of Dimebon, increased ΔΨm accompanied with 
increased cellular ATP levels was observed in both cell systems. Pretreatment with Dimebon 
made cells more resistant to calcium overload and loss of ΔΨm. Moreover, cells exhibited 
increased resistance towards induction of cell death after growth factor deprivation (see Figure 
8). Thereby, our study suggests that Dimebon affects the bioenergetics of the mitochondria and 
thereby protects cells against various cell stressors. Notably, resistance towards calcium stress 
was only observed in pretreated cells. Thus, Dimebon enhanced mitochondrial function, 
however, for optimal protection and for maintenance of cell viability, pretreatment is preferable. 
Recent studies on Dimebon have shown that Dimebon can ameliorate Aβ induced 
mitochondrial impairments (Eckert et al., 2012) and increase cerebral glucose utilization in 
aged mice (Day et al., 2011). These data further support Dimebon’s bioenergetic effects. Other 
modes of action have also been suggested including modulation of PTP (Bachurin et al., 2003), 
protection against Aβ toxicity (Bachurin et al., 2001), and decrease aggregation of TDP-43 and 
γ-synuclein (Yamashita et al., 2009; Bachurin et al., 2012). Interestingly, in three model 
systems Dimebon treatment was shown to increase the secretion of Aβ. The treatment of 
APPSwe overexpressing cells and synaptoneurosomes isolated from APPSwe/Ind mice (1-10 min or 
6 h with Dimebon) elevated the secretion of Aβ. Injection of Dimebon into the brains of APPSwe 
mice showed a 40% increase in Aβ40 in interstitial fluid 10 h post-injection (Steele et al., 
2009). Increasing Aβ secretion could be beneficial since secretion has been associated with 
neuroprotection in contrast to intracellular Aβ accumulation, which causes severe damage 
(Nilsson, Poster, AAIC, 2012, Vancouver, Canada). By strengthening the mitochondria and 
increasing Aβ secretion from neurons, Dimebon exhibits properties that could be important for 
generating disease-modifying effects. Unfortunately, as described earlier, Dimebon has recently 
failed two Phase III AD clinical trials (www.alzforum.org/new/detail.asp?id=2387). 
Nevertheless, the rich pharmacological profile of Dimebon is a basis to suggest it could be 
effective against other neurodegenerative diseases such as Huntington disease and neurological 
diseases like Schizophrenia. A Phase II clinical trial for Huntington disease has shown 
promising results (Kieburtz et al., 2010). Also a recent Phase II clinical trial for Schizophrenia, 
in which Dimebon was administered as an add-on to risperidone therapy, showed positive 
outcome. Several cognitive measures were improved possibly via serotonin receptor (5-HT6) 
blockage (Morozova et al., 2012).  
 
Drugs restoring the function of mitochondria and/or MAM might have disease-modulatory 
effect. The importance of a proper interaction between ER and mitochondria is evident as 
demonstrated in two other neurodegenerative diseases: GM1-gangliosidosis and Charcot-
Marie-Tooth neuropathy type 2a. In GM1-gangliosidosis, GM1-ganglioside accumulates in 
MAM where the interaction with IP3R leads to clustering of IP3R and increased calcium 
signaling resulting in calcium-dependent mitochondrial apoptosis (Sano et al., 2009). Charcot-
Marie-Tooth neuropathy type 2a is a disease caused by missense mutations in Mfn2. The 
interaction between ER and mitochondria depend on Mfn2 and absence of Mfn2 diminishes 
these interactions, thereby hampering calcium signals to the mitochondria. It is speculated that 
the mutations causing the disease might involve similar mechanisms (Zuchner et al., 2004; de 
Brito and Scorrano, 2008). Hence, the understanding of MAM per se and in regards to 
mitochondrial function is just in the beginning and research in this field might shed light to 
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several pathophysiological mechanisms involved in AD as well as other neurodegenerative 
diseases. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
In many respects, neurons, to sustain proper function, depend on an ability to form and maintain 
synapses, an operation which requires adequate energy supply and calcium handling. 
Mitochondria are the main energy providers in the brain and are the site for numerous 
biosynthetic and catabolic pathways essential for cell function. Their distribution is thought to 
be controlled by local energy and metabolic demand. Maintaining sufficient energy and 
metabolic supply to all cellular regions throughout the cell is a great challenge and becomes 
exceedingly difficult in polarized cells like neurons. Consequently, efficient control of 
mitochondrial distribution and expedient transport in response to different needs is essential for 
neuronal development and survival. Recently, it become clear that the mitochondrion does not 
act entirely alone; it needs to interact with ER to enable many processes. ER distribution is, as 
well, heavily regulated to ensure transport to all cellular regions. At the MAM region, ER 
interacts with the mitochondria, ensuring proper regulation of glucose, phospholipid and 
cholesterol metabolism, calcium homeostasis and apoptosis. All of these processes are known 
to be defective in AD. Since it is well established that mitochondrial bioenergetics and function 
are deranged already at early stages of AD, it is possible that alterations in MAM function may 
partly underlie these defects.  
 
We have detected MAM in the synapse where calcium homeostasis, energy metabolism and 
cell death signaling needs to be heavily regulated. With the knowledge that synapse dysfunction 
and synapse loss are events correlating best with cognitive impairments, we speculate that 
MAM function plays a pivotal role in synaptic integrity. Both dysfunctional mitochondria and 
aberrant caspase activation are prominent features of synapse dysfunction (Wei et al., 2010; 
Zempel et al., 2010; Trushina et al., 2012). Caspase activation is important for synaptic 
reorganization, LTD, LTP and plasticity in the brain, where caspase cleavage of structural 
proteins, like the actin skeleton, enables change in morphology. The activity of caspases must, 
however, be heavily regulated so to not cause aberrant activation and execution of the cell death 
program. Since the feature of plasticity involves activation of caspases, this means that several 
proteins during the process of activation can be cleaved, including PS1 and tau. The formation 
of caspCTF and the consequent elevation in intracellular Aβ42/Aβ40 ratio might be an 
important factor in plasticity, particularly since Aβ has been reported to regulate AMPA 
receptor internalization. Also the cleavage of tau might enable microtubule derangement. In any 
case, caspase activity can, indeed, also cause both Aβ toxicity and tau hyperphosphorylation 
(Quintanilla et al., 2012). Already, minor changes in intracellular Aβ42/Aβ40 ratio have been 
shown to be detrimental (Masters and Selkoe, 2012) and both Aβ and caspase-cleaved tau 
impair mitochondria (Quintanilla et al., 2012). Since the γ-secretase complex, APP and BACE1 
are all located to MAM we speculate that Aβ from this location can easily be transported over 
to the mitochondria and then be imported via the TOM40 pore (Hansson Petersen et al., 2008) 
(see Figure 8). Moreover, we have detected caspCTF in MAM, which further suggests that the 
Aβ42/Aβ40 ratio could locally change in this region. Intra-mitochondrial Aβ accumulation is an 
early phenomenon in the synapses and might indeed be one of the reasons for dysfunction and 
loss.  
 
There are several polymorphisms in the TOMM40 gene that associates with increased risk of 
developing AD. Interestingly, TOMM40 and APOE are in linkage disequilibrium with each 
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other, making it hard to separate risks associated with either gene. In our study, we did not learn 
of any functional implications concerning the specific poly-T repeat-polymorphism that had 
attracted a lot of attention after its claimed association to disease onset of AD. However, there 
are several other polymorphisms that might affect the mitochondria function and, thereby, 
increase the susceptibility for developing AD.   
 
Based on our observations we hypothesize that Aβ can interfere with processes on the MAM 
side as well on the mitochondrial side, affecting bioenergetics, lipid metabolism, calcium 
signaling and cell death regulation in the vulnerable synapse, which depends on correct 
distribution and contact between the two organelles. Aβ produced at these spots can, in theory, 
either be of physiological benefit or be a cause of damage. The drug Dimebon, tested for a 
variety of neurological disorders, has a wide pharmacological profile enhancing inter alia 
mitochondrial bioenergetics and Aβ secretion. These characteristics might definitely be of 
importance for disease-modifying treatments aiming to reestablish synaptic integrity by 
restoring mitochondrial function and decreasing intracellular Aβ levels. The reason for the 
failure of Dimebon in the Phase III clinical trials might be due to the fact that treatment at the 
stage of mild-to-moderate AD is too late. At this stage, restoring synaptic and neuronal function 
is difficult due to the advanced pathology. In conclusion, we believe that drugs targeting MAM 
and/or the mitochondria could serve as potential disease-modifying therapies. Drugs that have 
the capacity to restore mitochondrial glucose and lipid metabolism, calcium homeostasis and 
cell death signaling could potentially prevent synaptic dysfunction and loss. For efficacy, 
therapy should be started at the earliest possible disease stage, preferably before the mild-to-
moderate stage. However, many important questions remain concerning the nature of 
communication at MAM in regards to AD, and in what ways it might be possible to 
therapeutically intervene. 
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